


Europäisches
Patentamt

European Patent
Office

PCT/EP2004/000647.1
Office européen
des brevets

EP04/6471



**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.

The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag, den
The Hague,
La Haye, le

21. 09. 2004

Der Präsident des Europäischen Patentamts
Im Auftrag
For the President of the European Patent Office
Le Président de l'Office européen des brevets
p.o.

CLAUDIA ARAGONE

Patentanmeldung Nr.
Patent application no.
Demande de brevet n°

PCT/EP 03/06616

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°:

PCT/EP 03/06616

Anmelder:
Applicant(s):
Demandeur(s):

1. AXOVAN LTD. - Allschwil, Switzerland
2. HOUILLE, Olivier - Magdtatt Le Bas, France (US only)
3. FRETZ, Heinz - Riehen, Switzerland (US only)

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Pyrazolidinedione derivatives

Anmeldetag:
Date of filing:
Date de dépôt:

24 June 2003 (24.06.2003)

In Anspruch genommene Priorität(en)
Priority(ies) claimed
Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)
Designation of contracting states : See Form PCT/RO/101 (enclosed)
Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:
Remarks:
Remarques:

Further applicant:

4. HILPERT, Kurt - Hofstetten, Switzerland (US only)
5. RIEDERER, Markus - Liestal, Switzerland (US only)
6. GILLER, Thomas - Wintersingen, Switzerland (US only)

The application was transferred from the above-mentioned original applicant 1 to:
 ACTELION LTD. - Allschwil, Switzerland.
 The registration of the changes has taken effect on 18.02.2004.

Sheet No. ...3...

Box No. V DESIGNATION OF STATES

Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT (if other kind of protection or treatment desired, specify on dotted line)
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, BG Bulgaria, CH & LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, SI Slovenia, SK Slovakia, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | | |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda | <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> OM Oman |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> PH Philippines |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> AT Austria + utility model | <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> IS Iceland | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> SC Seychelles |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> BG Bulgaria | <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> KR Republic of Korea | <input checked="" type="checkbox"/> SK Slovakia + utility model |
| <input checked="" type="checkbox"/> BZ Belize | <input checked="" type="checkbox"/> KZ Kazakhstan | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> LR Liberia | <input checked="" type="checkbox"/> TN Tunisia |
| <input checked="" type="checkbox"/> CO Colombia | <input checked="" type="checkbox"/> LS Lesotho | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> CR Costa Rica | <input checked="" type="checkbox"/> LT Lithuania | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> LU Luxembourg | <input checked="" type="checkbox"/> TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> CZ Czech Republic + utility model | <input checked="" type="checkbox"/> LV Latvia | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> DE Germany + utility model | <input checked="" type="checkbox"/> MA Morocco | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> DK Denmark + utility model | <input checked="" type="checkbox"/> MD Republic of Moldova | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> DM Dominica | <input checked="" type="checkbox"/> MG Madagascar | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> DZ Algeria | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia | <input checked="" type="checkbox"/> VC Saint Vincent and the Grenadines |
| <input checked="" type="checkbox"/> EC Ecuador | <input checked="" type="checkbox"/> MN Mongolia | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> EE Estonia + utility model | <input checked="" type="checkbox"/> MW Malawi | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> MX Mexico | <input checked="" type="checkbox"/> ZA South Africa |
| <input checked="" type="checkbox"/> FI Finland + utility model | <input checked="" type="checkbox"/> MZ Mozambique | <input checked="" type="checkbox"/> ZM Zambia |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> NO Norway | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> GD Grenada | | |
| <input checked="" type="checkbox"/> GE Georgia | | |
| <input checked="" type="checkbox"/> GH Ghana | | |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

- ☒ NI Nicaragua
- ☒ PG Papua New Guinea

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Pyrazolidinedione derivatives

5

The present invention relates to alkyldene pyrazolidinedione derivatives which are effective platelet ADP receptor antagonists and can be used for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

10

Hemostasis is referred to as the cooperation of complex, interrelated events maintaining the fluidity of the blood in the vascular system while allowing the rapid formation of a solid blood clot to prevent excessive blood loss (hemorrhage) subsequent to blood vessel injury. Immediately after vascular damage, a cascade of processes is initiated, such as contraction of the vessels, platelet adhesion and aggregation, activation of the coagulation cascade and later also of the fibrinolytic system. Hemostasis is initiated by adhesion of blood platelets or thrombocytes to the exposed, highly thrombogenic, subendothelial connective tissue of the damaged vessels and aggregate to form a platelet plug to stop bleeding.

20

25

Pathological malfunction of hemostasis can result in developing of an unwanted, in some instances life-threatening, intravascular thrombus. Conditions such as turbulent blood flow in diseased vessels, disruption of underlying vessel wall, for example most commonly due to arteriosclerosis, exposure of damaged endothelial cells and release of mediators from circulating cells, activate platelet adhesion and aggregation resulting in arterial

30

35

thrombus formation and hence block off arterial blood vessels causing serious disease. Thrombi also form as a consequence of stasis or slow blood flow in veins. Venous thrombi can easily embolize, that means portions of them detach and travel through the circulatory system eventually blocking other vessels. Venous thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, unstable angina, myocardial infarction, stroke, cerebral embolisms, kidney and pulmonary embolisms are serious conditions that are the common cause of death and disability in patients with vascular disease.

Initial stimuli, such as thrombin, collagen, von Willebrand factor (vWf), thromboxane A₂ (TxA₂) and ADP, activate platelets by binding to their respective cell surface receptors. Many of these receptors belong to the family of seven transmembrane helices containing G-protein-coupled receptors, and their importance in platelet activation has been demonstrated (Offermans, S. et al., Nature 1998, 389 (11), 183-185). Upon activation, platelets change shape from a disc shape to a round form with pseudopodia, which enforces subsequent platelet adhesion and aggregation. The final common event of aggregation culminates in cross-linking the platelets by binding of fibrinogen to its receptor, glycoprotein IIb-IIIa (GPIIb-IIIa, integrin $\alpha_{IIb}\beta_3$) receptor.

A series of antiplatelet agents have been developed over the past several years (see review, Dogné et al., Curr. Med. Chem. 2002, 9(5), 577-589). One of the first and so far most widely used agents in antiplatelet therapy is aspirin, which irreversibly inhibits the enzyme cyclooxygenase-1 and thereby affecting the TxA₂ pathway. Although not optimally efficacious, treatment with aspirin remains the standard therapy against which new therapeutics are compared and judged. Following aspirin, the phosphodiesterase inhibitors dipyridamole and cilostazol

have been introduced as antiplatelet agents. Antiplatelet efficacy was also obtained with antibodies against the GPIIb/IIIa receptor (The EPIC investigators, New Engl. J. Med. 1994, 330, 956-961). Currently, three intravenously applicable, potent GPIIb/IIIa receptor antagonists (abciximab, eptifibatide, and tirofiban) blocking platelet aggregation are available on the market. In addition, orally active GPIIb/IIIa antagonists like sibrafiban, xemilofiban, and orbofiban were under clinical evaluation but have not been successful so far. Indirect or direct thrombin inhibitors, e.g. unfractionated heparin, low molecular weight heparins, hirudin, have also been shown to act as highly effective antithrombotic agents (Wong G.C. et al., JAMA 2003 Jan 15, 289(3), 331- 42; Antman E.M., Circulation 1994, 90, 1624- 1630, (GUSTO) IIa Investigators, Circulation 1994, 90, 1631-1637, Neuhaus K. L. et al., Circulation 1994, 90, 1638-1642).

Adenosine 5'-diphosphate (ADP) was identified as a key mediator in platelet activation and aggregation acting on at least two platelet ADP receptors of the G-protein coupled P2 receptor family (Shaver S. R., Curr. Opin. Drug Discovery & Development 2001, 4 (5), 665-670). The P2Y₁ receptor initiates aggregation through mobilization of calcium stores and is required for platelet shape change. The more recently identified P2Y₁₂ receptor, also denoted P2Y_{ADP}, P2Y_{AC}, P2Y_{cyc}, P_{2T}, P2T_{AC}, (see review, Barnard E. A. and Simon J., Trends Pharmacol. Sci. 2001, 22 (8), 388-391), mediates inhibition of adenylyl cyclase and is essential for full aggregation response to ADP and the stabilization of aggregates (Gachet Ch., Thromb Hemost. 2001, 86, 222-32; Turner N. A. et al., Blood 2001, 98 (12), 3340-3345; Remijn J. A. et al., Arterioscler. Thromb. Vasc. Biol. 2002, 22, 686-691).

A variety of antagonists of the platelet ADP receptor displaying inhibition of platelet aggregation and antithrombotic activity have been reported. So far, the

most effective antagonists known are the thienopyridines ticlopidine, clopidogrel and CS-747, which have been used clinically as antithrombotic agents (Kam and Nethery, Anaesthesia 2003, 58, 28-35; CAPRIE Steering Committee, The Lancet 1996, 348, 1329-39; Doggrell S. A., Drugs of the Future 2001, 26 (9), 835-840). It has been demonstrated that these drugs irreversibly block the adenosine 5'-diphosphate (ADP) receptor subtype P2Y₁₂ via their reactive metabolites.

Some analogues of the endogenous antagonist ATP, for example AR-C (formerly FPL or ARL) 67085MX and AR-C69931MX (Cangrelor), reached phase II clinical studies. These inhibitors are selective platelet ADP receptor antagonists, which inhibit ADP-dependent platelet aggregation, and are effective in vivo (see review, Chattaraj S. C., Curr. Opin. Invest. Drugs, 2001, 2(2), 250-255).

Laibelman A. M. et al. (PCT application WO 99/36425, published July 22, 1999) disclose fused heterotricyclic compounds, which are effective platelet ADP receptor inhibitors.

Hardern D. et al. (PCT application WO 01/36438, published May 25, 2001) disclose a series of triazolo[4,5-d]pyrimidines active as ADP receptor antagonists.

Scarborough and Marlowe (PCT application WO 01/85722, published November 15, 2001) disclose tricyclic benzothiazolo[2,3-c]thiadiazine derivatives, which are effective inhibitors of the platelet ADP receptor (P2Y₁₂).

Boyer et al. (PCT application WO 02/16381, published February 28, 2002, and US 2002/0052377, published May 2, 2002) disclose mononucleoside and dinucleoside polyphosphates as P2Y₁₂ receptor antagonists.

Bryant J. et al. (PCT application WO 02/098856, published December 12, 2002) disclose quinoline derivatives, useful as antithrombotic agents via inhibition of the platelet ADP receptor.

5

Scarborough R. M. et al. (PCT application WO 03/011872, published February 13, 2003) disclose sulfonylurea and sulfonamide derivatives, which are effective platelet ADP receptor inhibitors.

10

Alkylidene 3,5-pyrazolidinediones, the class to which the compounds of the present invention belong, have been known for a long time (Michaelis A. and Burmeister R. Ber. 1892, 1502-1513). However, the derivatives described herein display hitherto unknown biological effects, and parts of them are novel.

15

Bombrun A. et al. (PCT application WO 02/102359, published December 27, 2002) disclose the use of alkylidene pyrazolidinedione derivatives for the treatment and /or prevention of diabetes type I and/or II, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, and polycystic ovary syndrome via inhibition of phosphotyrosine phosphatases (PTPs), in particular PTP1B, TC-PTP, SHP and GLEPP-1.

20

25

Hassan S. (Canadian patent application CA 2,012,634, published September 20, 1991) claims alkylidene pyrazolidinedione derivatives blocking platelet activating factor (PAF) and leukotriene D4 (LTD4).

30


Krogdal T. G. (PCT application WO 00/54771, published September 21, 2000) discloses 3,5-pyrazolidinedione derivatives to combat viral infections.

35

In conclusion, moderate oral efficacy and adverse effects like serious bleeding problems limit the use of the currently known anti-platelet and anticoagulant agents.

There remains a pronounced medical need for more effective, orally active therapeutic modalities that can be used in the prevention and/ or treatment of vascular diseases, particularly those related to thrombosis, with minimal side effects. In particular, there is a need for potent, selective, reversible and orally active platelet ADP receptor (P2Y₁₂) receptor antagonists. The present invention provides compounds with such valuable pharmacological properties.

In one aspect the present invention relates to the use of pyrazolidinedione derivatives of the general formula



(I)

wherein

R₁ is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; and

R₂ is aryl or heteroaryl;

tautomers thereof;

geometric isomers thereof and tautomers of these geometric isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric

isomers, or tautomers thereof;

pharmaceutically acceptable acid addition salts of compounds which are basic;


pharmaceutically acceptable salts of compounds containing acidic groups with bases;

pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups;

prodrugs of compounds in which a prodrug forming group is present; as well as hydrates or solvates thereof; as platelet adenosine diphosphate receptor antagonists for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis, and, respectively, for the manufacture of corresponding medicaments.

10


The aforementioned geometric isomers of the compounds of formula (I) have the following formula (II)




(II)

and the aforementioned tautomers of the two geometric isomers of formulae (I) and (II) have the following formulae (IA) and (IIA), respectively.

15



(IA)




(IIA)

20 In the compounds of formula (I) R₁ is preferably hydrogen, alkyl, aryl or heteroaryl, particularly hydrogen, alkyl, phenyl, bromophenyl, chlorophenyl, fluorophenyl, methylphenyl, methoxyphenyl, cyanophenyl, alkoxy carbonylphenyl or pyridinyl, more particularly
25 hydrogen, methyl, phenyl, 2-pyridinyl, 4-pyridinyl, 2-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 2-

chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 4-cyanophenyl or 4-ethoxycarbonylphenyl.

R_2 is preferably naphthalen-2-yl, thienyl or pyridyl, particularly naphthalen-2-yl, pyridin-3-yl or thiophen-3-yl.

Particularly preferred is the use of use of compounds of the general formula



(III)

including their geometric isomers and tautomers and mixtures thereof as well as their salts, esters and prodrugs mentioned hereinabove, wherein R_1 is as defined hereinabove; R_3 is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy; and R_4 and R_5 , each independently of the other, are hydrogen, halogen, hydroxy, alkyl or alkoxy, or, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system.

In one aspect R_3 and R_5 in formula (III) each may be hydrogen and R_4 may be alkoxy, preferably methoxy; or R_3 and R_4 each may be hydrogen and R_5 may be alkoxy, preferably methoxy; or R_3 may be hydrogen, R_4 may be alkoxy, preferably methoxy, and R_5 may be hydroxy.

In a further aspect R_3 in formula (III) may be alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy and R_4 and R_5 both may be hydrogen, or R_4 may be halogen, alkyl or alkoxy and R_5 may be hydrogen, or R_4 and R_5 each independently may be alkyl or alkoxy. In this aspect R_3 is preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy, and preferably R_4 and R_5 both are hydrogen or R_4 is chloro, bromo, methyl or methoxy and R_5 is hydrogen, or R_4 and R_5 each independently are methyl or methoxy.

In a still further aspect R_3 in formula (III) may be hydrogen or alkoxy and R_4 and R_5 together with the phenyl ring to which they are attached, may form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1H-indene, dihydro-benzo[1,4]dioxine or benzo[1,3]dioxole moiety. In this aspect R_3 is preferably propoxy and R_4 and R_5 together with the phenyl ring to which they are attached, preferably form a naphthalene-1-yl or 5,6,7,8-tetrahydronaphthalen-1-yl moiety.


Particularly preferred is the use of 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione; 1-phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylenes)-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione; 4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylenes)-pyrazolidine-3,5-dione; 4-(2,3-dimethyl-4-methoxybenzylidene)-1-phenyl-pyrazolidine-3,5-dione; 4-(2,4-dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

- 4-(4-ethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(3-methyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
5 4-(4-butoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(4-hexyloxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(3-methyl-4-pentyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
10 4-(4-cyclopropylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione;
15 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzonitrile;
1-(2-chloro-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;
20 4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-pentyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
25 1-phenyl-4-(4-propoxy-naphthalen-1-ylmerthylene)-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-pentyl-benzylidene)-pyrazolidine-3,5-dione;
4-(4-propoxy-naphthalen-1-ylmethylen)-pyrazolidine-3,5-dione;
30 1-phenyl-4-(4-propoxy-benzylidene)-pyrazolidine-3,5-dione;
4-(4-butoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(4-cyclobutylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
35 4-[3-methyl-4-(3-methyl-butoxy)-benzylidene]-1-phenyl-pyrazolidine-3,5-dione;
4-(4-isobutoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

- 4- (4-cyclopentyloxy-2,3-dimethyl-benzylidene) -1-phenyl-
pyrazolidine-3,5-dione;
4- (3-methyl-4-propoxy-benzylidene) -1-pyridin-2-yl-
pyrazolidine-3,5-dione;
5 4- (2,3-dimethyl-4-propoxy-benzylidene) -1- (4-methyl-phenyl) -
pyrazolidine-3,5-dione;
4- (4-cyclopentyloxy-2,3-dimethyl-benzylidene) -pyrazolidine-
3,5-dione;
4- (2,3-dimethyl-4-propoxy-benzylidene) -1-pyridin-4-yl-
10 pyrazolidine-3,5-dione; and
4- (2,3-dimethyl-4-pent-1-ynyl-benzylidene) -pyrazolidine-
3,5-dione.

Compounds of the above general formula (III) wherein R₃, R₄
15 and R₅ are other than hydrogen are novel, with the
exception of 4- (4-hydroxy-naphthalen-1-ylmethylene) -1- (4-
iodo-phenyl) -pyrazolidine-3,5-dione and 1-phenyl-4- (2,3,4-
trimethoxy-benzylidene) -pyrazolidine-3,5-dione. In a
particular aspect the present invention thus relates to
20 these novel compounds per se as well as for use as
pharmaceutically active ingredients; to pharmaceutical
compositions containing one or several of these novel
compounds; to the use of these novel compounds as platelet
adenosine diphosphate receptor antagonists for the
25 prevention and/or treatment of peripheral vascular, of
visceral-, hepatic- and renal-vascular, of cardiovascular
and of cerebrovascular diseases and conditions associated
with platelet aggregation, including thrombosis, and,
respectively, for the manufacture of corresponding
30 medicaments; and to the manufacture of these novel
compounds.

The novel compounds provided by the present invention are
compounds of the general formula



(III)

including their geometric isomers and tautomers and mixtures thereof as well as their salts, esters and prodrugs mentioned hereinabove, wherein

R₁ is as defined hereinabove;

R₃ is alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy; and

R₄ and R₅, each independently of the other, are halogen, hydroxy, alkyl or alkoxy, or, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system, with the proviso that

(i) if R₁ is 4-iodophenyl and R₃ is hydroxy, R₄ and R₅ together with the phenyl ring to which they are attached may not be naphthalen-1-yl and

(ii) if R₁ is phenyl and R₃ is methoxy, R₄ and R₅ may not both be methoxy.

In one preferred sub-group of these novel compounds R₃ may be alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy, R₄ may be halogen, alkyl or alkoxy and R₅ may be alkyl or alkoxy.

Preferably R₃ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, cyclopropylmethoxy,

cyclobutylmethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy, R₄ is chloro, bromo, methyl or methoxy, and R₅ is methyl or methoxy.

In another preferred sub-group of these novel compounds R_3 may be alkoxy and R_4 and R_5 together with the phenyl ring to which they are attached, may form an optionally
5 substituted naphthalene, tetrahydronaphthalene, indane, 1H-indene, dihydro-benzo[1,4]dioxine or benzo[1,3]dioxole ring system. Preferably R_3 is propoxy and R_4 and R_5 together with the phenyl ring to which they are attached, form a
10 naphthalene-1-yl or 5,6,7,8-tetrahydronaphthalen-1-yl moiety.

Preferred novel compounds include 4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-methyl-phenyl)-
15 pyrazolidine-3,5-dione;
4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-4-yl-pyrazolidine-3,5-dione; and
20 4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-pyrazolidine-3,5-dione.

Particularly preferred novel compounds include 4-(2,3-dimethyl-4-methoxybenzylidene)-1-phenyl-pyrazolidine-3,5-
25 dione;
4-(2,4-dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione;
30 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzonitrile;
1-(2-chloro-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-
35 dione;
4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pentyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

1-phenyl-4-(4-propoxy-naphthalen-1-ylmerthylene)-pyrazolidine-3,5-dione;


5 4-(2,3-dimethyl-4-pentyl-benzylidene)-pyrazolidine-3,5-dione; and

4-(4-propoxy-naphthalen-1-ylmethyle)ne)-pyrazolidine-3,5-dione.

10 Most preferred novel compounds include 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione; 1-phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethyle)ne)-pyrazolidine-3,5-dione;

15 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione; and 4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethyle)ne)-pyrazolidine-3,5-dione.

20 In accordance with the present invention the aforementioned novel compounds can be manufactured by condensing a pyrazolidinedione of the general formula (IV), as shown in the following reaction scheme,



25 with an aldehyde of the above general formula (V).

Some of the starting materials of the above general formulae (IV) and (V) are novel and also form part of the present invention. These novel starting materials include the following pyrazolidinediones of the general formula (IV):

30 1-pyridin-2-yl-pyrazolidine-3,5-dione;

- 1- (4-methoxy-phenyl) -pyrazolidine-3,5-dione;
4- (3,5-dioxo-pyrazolidin-1-yl) -benzonitrile;
1- (2-methyl-phenyl) -pyrazolidine-3,5-dione; and
1-pyridin-4-yl-pyrazolidine-3,5-dione;
5 and the following aldehydes of the general formula (V)
4-cyclopentyloxy-2,3-dimethyl-benzaldehyde;
4-propoxy-5,6,7,8-tetrahydro-naphthalene-1-
carbaldehyde;
2,3-dimethyl-4-pent-1-ynyl-benzaldehyde; and
10 2,3-dimethyl-4-pentyl-benzaldehyde.

Unless explicitly stated otherwise, the general terms and
names used hereinbefore and hereinafter preferably have
within the context of this disclosure the following
15 meanings:

The term "alkyl", as used herein, alone or in any
combination, refers to a saturated aliphatic group
including a straight or branched hydrocarbon chain
20 containing 1-8 carbon atoms. Representative examples of
alkyl include, but are not limited to, methyl, ethyl, n-
propyl, iso-propyl, n-butyl, tert-butyl, iso-butyl (or 2-
methylpropyl), cyclopropylmethyl, n-pentyl, iso-pentyl,
iso-amyl, n-amyl, n-hexyl, n-heptyl, n-octyl and the like.
25 The alkyl group can be optionally substituted with one or
more substituents, each independently selected from
alkenyl, alkoxy, alkoxycarbonyl, alkylcarbonyl,
alkylcarbonyloxy, alkylendioxy, alkylsulfinyl,
alkylsulfonyl, alkylthio, alkynyl, amino, aminocarbonyl,
30 aryl, arylalkenyl, arylalkyloxy, aryloxy, aryloxycarbonyl,
arylsulfinyl, arylsulfonyl, arylthio, carboxy, cyano,
formyl, halogen, haloalkoxy, heterocyclyl, hydroxy,
mercapto, nitro, and the like, appended to any carbon atom
of the alkyl moiety.

35 The term "lower alkyl", as used herein, alone or in any
combination, refers to alkyl groups with 1-4 carbon atoms.
Representative examples of lower alkyl include, but are not

limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl and the like.

The term "alkenyl", as used herein, alone or in any
5 combination, refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms with at least one carbon-carbon double bond ($R_aR_bC=CR_cR_d$). R_a-R_d refer to substituents, each individually and independently selected from hydrogen and alkyl, alkoxy, alkoxyalkyl and the like.
10 Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl and the like.

The term "alkylenedioxy", as used herein, alone or in any
15 combination, refers to a $-O(CH_2)_nO-$ group, wherein n is preferably 1 or 2, and wherein the oxygen atoms are appended to two adjacent carbon atoms of the parent molecular moiety. Representative examples of alkylenedioxy include, but are not limited to, methylenedioxy,
20 ethylenedioxy, and the like.

The term "alkynyl", as used herein, alone or in any combination, refers to a straight or branched hydrocarbon chain containing 2-8 carbon atoms with at least one carbon-
25 carbon triple bond ($R_a-C\equiv C-R_b$, R_a and R_b referring to substituents, each individually and independently selected from hydrogen and alkyl, alkenyl, alkoxy, alkoxyalkyl, and the like). Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 1-
30 butynyl, 3-butynyl, 2-pentynyl, and the like.

The term "alkoxy", as used herein, alone or in any combination, refers to an alkyl group appended to the parent molecular moiety through an oxygen bridge.
35 Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.

The term "alkoxyalkyl", as used herein, alone or in any combination, refers to an alkoxy group appended to the parent molecular moiety through an alkyl group.

Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, methoxymethyl, and the like.

The term "alkoxycarbonyl", as used herein, alone or in any combination, refers to an alkoxy group appended to the parent molecular moiety through a carbonyl group.

Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, and the like.

The term "alkoxycarbonylalkyl", as used herein, alone or in any combination, refers to an alkoxycarbonyl group appended to the parent molecular moiety through an alkyl group.

Representative examples of alkoxycarbonylalkyl include, but are not limited to, methoxycarbonylpropyl, ethoxycarbonylbutyl, 2-tert-butoxycarbonylethyl, and the like.

The term "alkylcarbonyl" or "acyl", as used herein, alone or in any combination, refers to an alkyl group appended to the parent molecular moiety through a carbonyl group.

Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, 1-oxopentyl, and the like.

The term "alkylcarbonylalkyl", as used herein, alone or in any combination, refers to an alkylcarbonyl group appended to the parent molecular moiety through an alkyl group.

Representative examples of alkylcarbonylalkyl include, but are not limited to, 2-oxopropyl, 3,3-dimethyl-2-oxopropyl, 3-oxobutyl, 3-oxopentyl and the like.

The term "alkylcarbonyloxy", as used herein, alone or in any combination, refers to an alkylcarbonyl group appended

to the parent molecular moiety through an oxygen bridge. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, tert-butylcarbonyloxy and the like.

5

The term "alkylsulfinyl", as used herein, alone or in any combination, refers to an alkyl group appended to the parent molecular moiety through a sulfinyl group.

Representative examples of alkylsulfinyl include, but are
10 not limited to, methylsulfinyl, ethylsulfinyl and the like.

The term "alkylsulfinylalkyl", as used herein, alone or in any combination, refers to an alkylsulfinyl group appended to the parent molecular moiety through an alkyl group.

15 Representative examples of alkylsulfinylalkyl include, but are not limited to, methylsulfinylmethyl, ethylsulfinylmethyl and the like.

The term "alkylsulfonyl", as used herein, alone or in any
20 combination, refers to an alkyl group appended to the parent molecular moiety through a sulfonyl group.

Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl, ethylsulfonyl, and the like.

25

The term "alkylsulfonylalkyl", as used herein, alone or in any combination, refers to an alkylsulfonyl group appended to the parent molecular moiety through an alkyl group.

Representative examples of alkylsulfonylalkyl include, but
30 are not limited to, methylsulfonylmethyl, ethylsulfonylmethyl and the like.

The term "alkylthio", as used herein, alone or in any combination, refers to an alkyl group appended to the
35 parent molecular moiety through a thio group.

Representative examples of alkylthio include, but are not limited to, methylthio, ethylthio, tert-butylthio, hexylthio and the like.

The term "alkylthioalkyl", as used herein, alone or in any combination, refers to an alkylthio group appended to the parent molecular moiety through an alkyl group.

- 5 Representative examples of alkylthioalkyl include, but are not limited to, methylthiomethyl, 2-(ethylthio)ethyl, and the like.

- 10 The term "amino", as used herein, alone or in any combination, refers to a $-NR_eR_f$ group, wherein R_e and R_f are substituents, each individually and independently selected from hydrogen, alkyl, aryl, arylalkyl, acyl, alkylcarbonyl, arylcarbonyl, carbamoyl, ureido, formyl, alkylsulfonyl, arylsulfonyl, and the like. Representative examples of
- 15 amino include, but are not limited to, dimethylamino, ethylamino, benzyl-(methyl)amino, and the like.

- The term "aminoalkyl", as used herein, alone or in any combination, refers to an amino group appended to the
- 20 parent molecular moiety through an alkyl group. Representative examples of aminoalkyl include, but are not limited to, aminomethyl, 2-(amino)ethyl, benzyl-(methyl)aminomethyl, dimethylaminomethyl, and the like.

- 25 The term "aminocarbonyl" or "amido", as used herein, alone or in any combination, refers to an amino group appended to the parent molecular moiety through a carbonyl group. Representative examples of aminocarbonyl include, but are not limited to, dimethylaminocarbonyl, benzyl-
- 30 aminocarbonyl, ethylaminocarbonyl, and the like.

- The term "aminocarbonylalkyl", as used herein, alone or in any combination, refers to an aminocarbonyl group appended to the parent molecular moiety through an alkyl group.
- 35 Representative examples of aminocarbonylalkyl include, but are not limited to, 2-amino-2-oxoethyl, 2-(benzylamino)-2-oxoethyl, 2-(methylamino)-2-oxoethyl, 4-amino-4-oxobutyl, 4-(dimethylamino)-4-oxobutyl, and the like.

The term "aryl", as used herein, alone or in any combination, refers to an carbocyclic group having at least one aromatic ring, e.g. phenyl or biphenyl, or multiple condensed ring systems, in which at least one ring is aromatic, e.g. 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, phenanthryl, fluorenyl, and the like. The aryl group may be optionally substituted with one or more functional groups individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, haloalkyl, heteroaryl, heterocyclyl, hydroxy, hydroxyalkyl, mercapto, nitro, and the like.

The term "arylalkenyl", as used herein, alone or in any combination, refers to an aryl group appended to the parent molecular moiety through an alkenyl group. The aryl group may be unsubstituted or substituted. Representative examples of arylalkenyl include, but are not limited to, 2-phenylethenyl, 3-phenylpropen-2-yl, 2-naphth-2-ylethenyl, and the like.

The term "arylalkoxy", as used herein, alone or in any combination, refers to an aryl group appended to the parent molecular moiety through an alkoxy group. The aryl group may be unsubstituted or substituted. Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 5-phenylpentyloxy, 3-naphth-2-ylpropoxy, and the like.

The term "arylalkyl", as used herein, alone or in any combination, refers to an aryl group appended to the parent molecular moiety through an alkyl group. The aryl group may be unsubstituted or substituted. Representative examples of arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-naphth-2-ylethyl, and the like.

10 The term "aryloxy", as used herein, alone or in any combination, refers to an aryl group appended to the parent molecular moiety through an oxygen bridge. The aryl group can be unsubstituted or substituted. Representative examples of aryloxy include, but are not limited to, 15 phenoxy, naphthyloxy, 3-bromophenoxy, 4-chlorophenoxy, 4-methylphenoxy, 3,4-dimethoxyphenoxy, and the like.

The term "carbamoyl", as used herein, alone or in any combination, refers to a $-C(O)NR_eR_f$ group. R_e and R_f are 20 substituents, each individually and independently selected from hydrogen, alkyl, arylalkyl, and the like.

Similarly, the term "thiocarbamoyl", as used herein, alone or in any combination, refers to a $-C(S)NR_eR_f$ group. 25

The term "carbonyl", as used herein, alone or in any combination, refers to a $-C(O)$ group.

The term "carboxy", as used herein, alone or in any combination, refers to a $-CO_2H$ group. 30

The term "carboxyalkyl", as used herein, alone or in any combination, refers to a carboxy group appended to the parent molecular moiety through an alkyl group. 35 Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2-carboxyethyl, 3-carboxypropyl, and the like.

The term "cyano", as used herein, alone or in any combination, refers to a $-C\equiv N$ group.

5 The term "cyanoalkyl", as used herein, alone or in any combination, refers to a cyano group appended to the parent molecular moiety through an alkyl group. Representative examples of cyanoalkyl include, but are not limited to, cyanomethyl, 2-cyanoethyl, 3-cyanopropyl, and the like.

10 The term "cycloalkyl", as used herein, alone or in any combination, refers to a saturated cyclic hydrocarbon moiety containing 3-15 carbon atoms, optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, 15 alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, 20 arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, halogen, haloalkoxy, 25 haloalkyl, heterocyclyl, hydroxy, hydroxyalkyl, mercapto, nitro, and the like. Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. In polycyclic cycloalkyl groups one of the distal 30 rings may be aromatic, e.g., 1-indanyl, 2-indanyl, tetrahydronaphthalene, and the like.

The terms "cycloalkenyl" and "cycloalkynyl", as used herein, alone or in any combination, refer to unsaturated 35 cyclic hydrocarbon moieties containing at least one carbon-carbon double or carbon-carbon triple bond, respectively. Such moieties may be optionally substituted with one or

more groups as discussed hereinabove for the cycloalkyl groups.

5 The term "formyl", as used herein, alone or in any combination, refers to a $-C(O)H$ group.

The term "formylalkyl", as used herein, alone or in any combination, refers to a formyl group, appended to the parent molecular moiety through an alkyl group.

10 Representative examples of formylalkyl include, but are not limited to, formylmethyl, 2-formylethyl, and the like.

15 The term "halo" or "halogen", as used herein, alone or in any combination, refers to fluorine, bromine, chlorine, and iodine.

The term "haloalkyl", as used herein, alone or in any combination, refers to an alkyl group having at least one hydrogen atom replaced with a halogen atom. Representative
20 examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and the like.

25 The term "haloalkoxy", as used herein, alone or in any combination, refers to an alkoxy group having at least one hydrogen atom replaced with a halogen atom. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, pentafluoroethoxy, and the like.

30

35 The term "heterocyclyl", as used herein, alone or in any combination, refers to a monocyclic, bicyclic or polycyclic ring system containing up to 15 ring atoms, at least one of these being a hetero atom independently selected from nitrogen, oxygen or sulfur. The ring system may be saturated, partially unsaturated, unsaturated or aromatic. Representative examples of heterocyclyl include, but are not limited to, furyl, imidazolyl, imidazolinyl,

imidazolidinyl, isothiazolyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrrolinyl, 5 pyrrolidinyl, tetrahydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolyl, thiazolyl, thiazolinyl, thiazolidinyl, thienyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, benzimidazolyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzofuranyl, indolyl, 10 indolinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoindolinyl, isoquinolinyl, quinolinyl, and the like. Defined heterocyclyl moieties may be optionally substituted with one or more groups, each individually and independently selected from alkenyl, alkoxy, alkoxyalkyl, 15 alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylendioxy, alkylsulfinyl, alkylsulfinylalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkylthio, alkylthioalkyl, alkynyl, amino, aminoalkyl, aminocarbonyl, aminocarbonylalkyl, aryl, 20 arylalkenyl, arylalkyloxy, arylalkyl, aryloxy, aryloxycarbonyl, aryloxycarbonylalkyl, arylsulfinyl, arylsulfinylalkyl, arylsulfonyl, arylsulfonylalkyl, arylthio, arylthioalkyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, formyl, formylalkyl, halogen, 25 haloalkoxy, haloalkyl, heterocyclyl, heteroaryl, hydroxy, hydroxyalkyl, mercapto, nitro, and the like.

The term "heteroaryl", as used herein, alone or in any combination, is a special case of heterocyclyl and refers 30 to a mono- or bicyclic or polycyclic aromatic ring system, in which at least one heterocyclic ring is aromatic.

The term "heterocyclylalkenyl", as used herein, alone or in any combination, refers to a heterocyclyl group appended to 35 the parent molecular moiety through an alkenyl group. Representative examples of heterocyclylalkenyl include, but are not limited to, 2-pyrid-3-ylethenyl, 3-quinolin-3-ylpropen-2-yl, 5-pyrid-4-ylpenten-4-yl, and the like.

The term "heterocyclylalkoxy", as used herein, alone or in any combination, refers to a heterocyclyl group appended to the parent molecular moiety through an alkoxy group.

5 Representative examples of heterocyclylalkoxy include, but are not limited to, 2-pyrid-3-ylethoxy, 3-quinolin-3-ylpropoxy, 5-pyrid-4-ylpentyloxy, and the like.

10 The term "heterocyclylalkyl", as used herein, alone or in any combination, refers to a heterocyclyl group appended to the parent molecular moiety through an alkyl group.

Representative examples of heterocyclylalkyl include, but are not limited to, 2-pyrid-3-ylmethyl, 2-pyrimidin-2-ylpropyl, and the like.

15

The term "heterocyclylloxy", as used herein, alone or in any combination, refers to a heterocyclyl group appended to the parent molecular moiety through an oxy group.

20 Representative examples of heterocyclylloxy include, but are not limited to, pyrid-3-yloxy, quinolin-3-yloxy, and the like.

25 The term "hydroxy" or "hydroxyl" as used herein, alone or in any combination, refers to an -OH group

25

30 The term "hydroxyalkyl", as used herein, alone or in any combination, refers to an alkyl group having at least one hydrogen atom replaced with a hydroxy group. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-ethyl-4-hydroxyheptyl, and the like.

The term "nitro", as used herein, alone or in any combination, refers to a -NO₂ group.

35

The term "oxo", as used herein, alone or in any combination, refers to a =O group.

The term "oxy", as used herein, alone or in any combination, refers to a -O- group.

5 The terms "mercapto" and "thiol", as used herein, alone or in any combination, refer to a -SH group.

The terms "thio", "sulfinyl" and "sulfonyl", as used herein, alone or in any combination, refer to a -S(O)_n group with n= 0, 1 and 2, respectively.

10 Within the scope of the present invention, unless indicated otherwise, compounds of formulae (I) and (III) or pharmaceutically acceptable salts thereof are included that may exist in, and be isolated in, isomeric forms, including
15 cis- or trans isomers or mixtures thereof, and tautomers. Other compounds of this invention may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms, and thus may give rise to optically pure enantiomers, mixtures of enantiomers,
20 racemates, enantiomer-pure diastereomers, mixtures of diastereomers, epimers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)-, (S)- or (R,S)-configured, preferably in the (R)- or (S)-configuration. Such isomers can be obtained by methods
25 within the knowledge of one skilled in the art, e.g. by stereochemically controlled synthesis using chiral synthons or chiral reagents, or by means of classical separation techniques, such as chromatographic or crystallization methods, or by other methods known in the art, such as
30 through formation of diastereomeric salts, for example by salt formation with an enantiomerically pure chiral acid, or by means of chromatography, for example by using chromatographic materials modified with chiral ligands. Furthermore, the present invention refers to compounds
35 containing centers of any geometric asymmetry, like, for example, unsymmetrically substituted olefinic double bond, including E or Z geometric isomers and mixtures thereof.

Generally, pure isomers of compounds of formulae (I) and (III) are preferred over isomeric mixtures.

In the present invention, the compounds of formulae (I) and (III) may be used in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to relatively nontoxic, inorganic or organic acid and base addition salts, which retain the biological effectiveness and properties of the parent compound, and which are not biologically or otherwise undesirable (see, e.g., Berge et al., J. Pharm. Sci. 1977, 66, 1-19).

Certain compounds of the present invention can contain one or more basic functional groups, such as amino, alkylamino, or arylamino, and, thus, be capable of forming pharmaceutically acceptable acid addition salts. These acid addition salts may be prepared by standard procedures in a suitable solvent from the parent compound of formula (I) or (III), with an appropriate amount of an inorganic acid, including, but not limited to, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, or phosphoric acid; or of an organic acid, including, but not limited to, acetic acid, propionic acid, octanoic acid, decanoic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, ascorbic acid, amino acids, such as glutamic acid or aspartic acid, benzoic acid, cinnamic acid, salicylic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, or other acidic organic compounds.

Certain compounds of the present invention may, on the other hand, contain one or more acidic functional groups and, thus, be capable of forming pharmaceutically acceptable base addition salts. These salts can be prepared by addition of an appropriate amount, usually in stoichiometric ratio, of an alkaline reagent, such as hydroxide, carbonate or alkoxide, containing the

appropriate cation, to the free acid in a suitable solvent. Preferred inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium or magnesium, also zinc salts and the like. Preferred salts derived from
5 organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines, cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine,
10 arginine, N-ethylpiperidine, piperidine, polyamine resins, and the like.

Compounds of the present invention containing both acidic and basic groups can also form internal salts (zwitter
15 ions).

For isolation or purification purposes, it is also possible to use pharmaceutically unacceptable salts, for example perchlorates, picolines, picrates, or the like. For
20 therapeutic use, only pharmaceutically acceptable salts or free compounds are employed, where applicable in the form of pharmaceutical preparations, and these are therefore preferred.

25 Certain compounds of formulae (I) and (III), including their salts, may exist in solvated as well unsolvated forms, such as, for example, hydrated forms, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be
30 present. The present invention encompasses all such solvated and unsolvated forms.

The present invention also relates to prodrug derivatives of the parent compounds of formulae (I) and (III). The term
35 "prodrug" refers to pharmacologically inactive precursors of a drug that may be converted into its therapeutically active form under physiological conditions *in vivo*, for example, when they undergo solvolysis, or enzymatic

degradation in blood, or in cells, (Bundgard H., "Design of Prodrugs", pp. 7-9, 21-24, Elsevier, Amsterdam (1985); Silverman R. B., "The Organic Chemistry of Drug Design and Drug Action", pp. 352-401, Academic Press, San Diego, CA (1992); Higuchi T. et al., "Pro-drug as Novel Delivery Systems", A.C.S. Symposium Series, Vol. 14). The term "prodrug" also includes any covalently bonded carriers, which release the active parent compound *in vivo* when administered to a mammal. Prodrug modifications of a compound often offer advantages of solubility, bioavailability, absorption, tissue compatibility, tissue distribution, or delayed release in the mammalian organism. Prodrugs are variations or derivatives of the compounds of formulae (I) and (III), which have groups cleavable under metabolic conditions, for example, pharmaceutically acceptable esters, or amides. Such groups can be cleaved enzymatically or non-enzymatically, or hydrolytically to the free hydroxy, carboxy, or amino group of the active parent compound. In another embodiment, the prodrug is a reduced form, which is oxidized *in vivo* to the therapeutic compound, for example, a thiol, which is oxidized to a sulfonate or sulfate, an alcohol to a carboxylic acid.

Further included within the scope of the present invention are pharmaceutically acceptable esters of the compounds of formulae (I) and (III). The term "pharmaceutically acceptable esters" refers to relatively non-toxic, esterified products of the parent compound. These esters can be prepared *in situ* during the final isolation and purification of the compounds, or by separately reacting the purified compounds in its free acid or hydroxyl form with a suitable esterifying agent. Carboxylic acids can be converted into esters *via* treatment with an alcohol in the presence of a catalyst. Hydroxyl containing derivatives can be converted into esters *via* treatment with an esterifying agent such as alkanoyl halides. The term further includes lower hydrocarbon groups capable of being solvated under

physiological conditions, for example, alkyl esters, preferred methyl, ethyl, and propyl ester, methoxymethyl ester, methylthiomethyl ester, pivaloyloxymethyl ester and the like (see, e.g., Berge et al., J. Pharm. Sci. 1977, 66, 1-19).

The compounds of the present invention have useful, in particular pharmacologically useful, properties. They are able to specifically antagonize the effect of endogenous ADP on its platelet ADP receptor, the $P2Y_{12}$ receptor. The platelet ADP receptor $P2Y_{12}$ upon activation with ADP is responsible for blood platelet aggregation. The compounds of formulae (I) and (III) are therefore useful in treatment or prevention of vascular diseases that respond to the blockade of the $P2Y_{12}$ receptor.

A compound or a pharmaceutical composition of the invention may be used as a drug (medicine) or therapeutic agent for prevention and/ or treatment of peripheral vascular, cardiovascular and cerebrovascular diseases or conditions, associated with platelet aggregation, particularly related to thrombosis in humans and other mammals. Such compounds may be useful as inhibitors of platelet activation, aggregation and degranulation, as anti-thrombotic agents or in the treatment and/or prevention of, for example any thrombosis, particularly platelet-dependent thrombotic indications, including, but not limited to, acute myocardial infarction, unstable angina, coronary angioplasty (PTCA), perithrombolysis, primary arterial thrombotic complications of atherosclerosis such as thrombotic or embolic stroke, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, myocardial infarction with or without thrombolysis, pre-eclampsia/ eclampsia, venous thrombosis such as deep venous thrombosis, venoocclusive disease, embolism, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, heparin-induced thrombocytopenia, hemolytic uremic syndrome, thrombotic

complications of septicemia, adult respiratory distress syndrome, anti-phospholipid syndrome, hematological conditions such as myeloproliferative disease, including thrombocytopenia; thrombotic and restenotic complications following invasive procedures, for example angioplasty, carotid endarterectomy, post coronary bypass graft surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prostheses, thrombotic complications of surgical or mechanical damage such as tissue salvage following accidental or surgical trauma, reconstructive surgery including skin and muscle flaps.

The compounds of the invention may also be used for the prevention of mechanically-induced platelet activation in vivo, for example to prevent microthromboembolism in cardiopulmonary bypass; or in vitro in the preservation of blood products, for example platelet concentrates; or shunt occlusion such as in renal dialysis and plasmapheresis, thrombosis secondary to vascular damage/ inflammation such as vasculitis, arteritis, glomerulonephritis, inflammatory bowel disease and organ graft rejection, conditions such as migraine, Raynaud's phenomenon, atheromatous plaque formation/progression, vascular stenosis/restenosis and asthma, in which platelet-derived factors play a role in the disease process.

In another aspect, the compounds of formulae (I) and (III) may be used as standard or reference compounds in tests or assays involving the inhibition of the platelet ADP receptor, $P2Y_{12}$. Such compounds could be made commercially available for use as a reference, quality standard or control, for example in pharmaceutical research when developing new assays or protocols related to $P2Y_{12}$ activity.

As mentioned earlier, compounds of formulae (I) and (III), or salts, or prodrugs thereof, antagonize the ADP dependent

activation of the platelet ADP receptor P2Y₁₂. The biological effect of such compounds may be tested in a variety of *in vitro*, *ex vivo* and *in vivo* assays.

5 The ability of the compounds of formulae (I) and (III) to bind to the P2Y₁₂ receptor may be measured by methods similar to those described in Gachet C. et al., Br. J. Hematol. 1995, 91, 434-444 and by the method described below in Example 15.

10

With this type of assay, IC₅₀ values (i.e. the concentrations where half-maximal inhibition of the interaction is found) in the range of 0.001 to 10 µM, preferably values below 1 µM, in particular values below

15 0.05 µM, are found with test compounds of formulae (I) and (III). Exemplary IC₅₀ values determined in this test are given below in Example 16.

20 The ability of the compounds of the invention to inhibit ADP-induced aggregation of platelets may be measured by methods similar to those described in (Born, G.V.R., and M.J. Cross. 1963, J. Physiol., Vol. 168:178- 195) and the method described below in Example 17.

25 With this type of assay, ED₅₀ (i.e. the effective dose where half-maximal inhibition of the aggregation is found) in the range of 0.05 to 5 µM, preferably values below 1 µM, in particular values below 0.1 µM, are found with test compounds of formulae (I) and (III).

30

A functional assay with cells expressing the human P2Y₁₂ receptor may be used to detect changes in the levels of intracellular calcium concentration following compound treatment. After addition of the compound the cells are
35 challenged with ADP. In a Fluorescent Imaging Plate Reader (FLIPR™, Molecular Devices, Sunnyvale, California) fluorescence emission is recorded during both additions,

emission peak values above base level after ADP addition were exported, normalized to low controls (no ADP) and high controls (no active compound). The relative values of the remaining activity were used to determine IC_{50} values by curve fitting them to a four-parameter logistic sigmoid curve.

Calculation

$$\% \text{ remaining activity} = \frac{(\% \text{ value with compound} - 0\% \text{ value})}{(100\% \text{ value} - 0\% \text{ value})} \times 100\%$$

- 10 The ability of the compounds to inhibit ADP induced change of intracellular calcium levels via $P2Y_{12}$ activation may be measured by methods known of one skilled in the art or by the method described below in Example 18.
- 15 With this assay, IC_{50} values (i.e. the concentration of a compound at which the remaining activity is 50%) in the range of 0.001 and 10 μM , preferably below 0.5 μM , are obtained with test compounds of formulae (I) and (III).
- 20 The results of these assays clearly demonstrate, that the present invention provides functional antagonists of the $P2Y_{12}$ receptor inhibiting platelet aggregation, and therefore may be useful for the treatment of vascular diseases, particularly thrombosis.
- 25 On the basis of the biological studies discussed hereinabove, a compound of formula (I) or (III) according to the invention may show therapeutic efficacy against vascular disorders mentioned herein, especially against
- 30 thrombotic diseases.
- A compound of formula (I) or (III), a pharmaceutically acceptable salt or a prodrug thereof, can be administered alone in pure form or in combination with one or more other
- 35 therapeutic agents, possible combination therapy taking the form of fixed combinations or the administration of a

compound of the invention and one or more other therapeutic agents being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic agents. A
5 compound of formula (I) or (III) can besides or in addition be administered especially for anti-thrombotic therapy in combination with other vascular diseases. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above.
10 Other possible treatments are preventive therapies, for example in patients at risk.

The invention relates also to pharmaceutical compositions comprising compounds of formula (III), to their use in
15 therapeutic, in a broader aspect of the invention also prophylactic treatment or a method of treatment of the diseases mentioned above, to the compounds for said use and to the preparation of pharmaceutical formulations (medicines).

20 The pharmaceutically acceptable compounds of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of the active ingredient together or in admixture
25 with a significant amount of one or more inorganic, organic, solid or liquid, pharmaceutically acceptable carriers.

The invention relates also to a pharmaceutical composition
30 that is suitable for administration to a warm-blooded animal, especially a human (or to cells or cell lines derived from a warm-blooded animal, especially a human, e.g. blood platelets), for the treatment or, in a broader aspect of the invention, prevention of (i.e. prophylaxis
35 against) a disease that responds to blockade of the interaction of the platelet adenosine diphosphate (ADP) receptor with ADP, comprising an amount of a compound of formula (I) or (III) or a pharmaceutically acceptable salt

or a prodrug thereof, which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier.

- 5 The pharmaceutical compositions according to the invention are those for enteral administration, such as nasal, buccal, rectal, dermal or, especially oral administration, and for parenteral administration, such as intramuscular, intravenous or subcutaneous, intrasternal, intravitreal, injection or infusion, to warm-blooded animals, especially humans. Such compositions comprise an effective dose of the pharmaceutically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dosage of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual conditions, individual pharmacokinetic data, the disease to be treated and the mode of administration.
- 15
- 20 The invention relates also to a process or a method for the treatment of a pathological condition mentioned hereinabove, especially a disease, which responds to blockade of the interaction of the platelet adenosine diphosphate (ADP) receptor with ADP, especially thrombosis.
- 25 The compounds of formulae (I) and (III) or salts or a prodrugs thereof can be administered as such or especially in the form of pharmaceutical compositions.

The dose to be administered to warm-blooded animals, for example humans of approximately 70 kg body weight, is preferably from approximately 3 mg to approximately 30 g, more preferably from approximately 10 mg to approximately 1000 mg per person per day, divided preferably into 1 to 3 single doses which may, for example, be of the same size. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of

30

35

administration, the actual compound administered, the age, the weight, and response of the individual patient, the severity of the patient's symptoms, and the like, for example, children usually receive half of the adults dose.

5

The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dosage forms such as coated and uncoated tablets, pills, ampoules, vials, suppositories, dragées, or capsules. Further dosage forms are, for example, ointments, creams, pastes, emulsions, foams, chewable gums, tinctures, lip-sticks, drops, sprays or aerosols, syrups or elixirs, dispersions, transdermal patches or pads, or via an intravitreal device that releases the compound in a sustained capacity, and the like. Examples are capsules containing from about 0.05 g to about 1.0 g active ingredient.

20

The pharmaceutical compositions of the present invention are prepared in a manner known, *per se*, for example by means of conventional mixing, granulating, coating, dissolving, lyophilizing or confectioning processes.

25

Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions, are preferably used, it being possible, for example in the case of lyophilized compositions, that comprise the active ingredient alone or together with a carrier, for example mannitol, for such solutions or suspensions to be produced prior to use. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known *per se*, for example by means of conventional dissolving or

30

35

lyophilizing processes. The said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.

5 Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. There may be mentioned as such especially liquid fatty acid esters that contain as the
10 acid component a long-chain fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for
15 example oleic acid, elaidic acid, erucic acid, brasidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, β -carotene or 3,5-di-tert-butyl-4-hydroxytoluene. The alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is
20 mono- or poly-hydroxy, for example a mono-, di- or trihydroxy, alcohol, for example methanol, ethanol, propanol, butanol, or pentanol or the isomers thereof, but especially glycol and glycerol. The following examples of fatty acid esters are therefore to be mentioned: ethyl
25 oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M2375" (polyoxyethylene glycerol trioleate, Gattefossé, Paris), "Miglyol 812" (triglyceride of saturated fatty acids with chain length of C8 to C12, Hüls AG, Germany), but especially vegetable oils, such as cottonseed oil,
30 almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.

The injection or infusion compositions are prepared in customary manner under sterile conditions; the same applies
35 also to introducing the compositions into ampoules or vials and sealing the containers.

Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragée cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.

10 Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, 15 wheat, rice, or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, and/or carboxymethyl starch, crosslinked 20 polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragée cores 25 are provided with suitable, optionally enteric, coatings, there being used, inter alia, concentrated sugar solutions which may comprise gum Arabic, talc, polyvinylpyrrolidone, polyethylene glycol, and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the 30 preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Capsules are dry-filled capsules made of gelatin and of soft sealed capsules made of gelatine and a plasticiser, such as glycerol or 35 sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if

desired with stabilizers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oil excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for

5 stabilizers and/or antibacterial agents to be added. Dyes or pigments may be added to the tablets or dragée coatings or the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.

10

For parenteral administration, aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances and stabilizers,

15 are especially suitable. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and be made into a solution before parenteral administration by the addition of solvents.

20 Compounds of the invention may be manufactured by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by Larock R. C. in "Comprehensive organic transformations: a guide to

25 functional group preparations", VCH publishers, 1999.

In the reactions described hereinafter, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are


30 desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for example see Greene T. W. and Wuts P. G. M. in "Protective groups in organic synthesis" Wiley-

35 Interscience, 1999.

Generally, alkylidene pyrazolidinediones of formula (I) may be prepared by the condensation of pyrazolidinedione of


formula (IV) with an aldehyde of formula (V), optionally in the presence of a suitable base such as pyridine, piperidine, diisopropylethylamine, triethylamine, in a suitable solvent, such as ethanol, methanol, 1-butanol or acetic acid as shown in Scheme 1, hereinbelow. The preferred conditions are heating the pyrazolidinedione of formula (IV) with an aldehyde of formula (V) in ethanol between 60 to 80°C.

Scheme 1



Pyrazolidinediones of formula (IV) may be prepared as shown in Scheme 2, hereinbelow, by reacting an hydrazine of formula (VI) with a malonic derivative of formula (VII) whereby LG₁ and LG₂ could be any appropriate leaving groups such as halogen, or aliphatic or aromatic alkoxy groups.

Scheme 2




A preferred method to prepare compounds of formula (IV) is the cyclization of compounds of formula (VIII), by analogy with a method described by Michaelis A. and Burmeister R., Ber. 1892, 1502-1513, in the presence of an appropriate base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium carbonate, sodium hydride in a suitable solvent such as ethanol, methanol,

tetrahydrofuran or N,N-dimethylformamide as shown in Scheme 3, hereinbelow. The preferred conditions for the cyclization are stirring the compounds of formula (VI) at room temperature in ethanol in presence of sodium hydroxide.

Thus, compounds of formula (VIII) may be prepared by the condensation of hydrazines of formula (VI) with malonic acid derivatives of formula (VII), whereby LG_1 is an appropriate leaving group such as OH, in the presence of a coupling reagent, such as 1,3-dicyclohexylcarbodiimide, O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, or whereby LG_1 is any halogen in presence of a base such as triethylamine, N,N-diisopropylethylamine or pyridine in a suitable solvent such as tetrahydrofuran or N,N-dimethylformamide and LG_2 is an alkoxy or aryloxy group. The preferred conditions for the condensation step are adding a compound of formula (VII) whereby $LG_1=Cl$ and $LG_2=OEt$, to a solution of a hydrazine of formula (VIII) in tetrahydrofuran at a temperature of about $-10^{\circ}C$ in presence of triethylamine.

Scheme 3



Another preferred method to prepare compounds of formula (IV) is the condensation of hydrazines of formula (VI) with a dialkoxy malonate in a suitable solvent, like methanol or ethanol, in presence or absence of a base such as sodium methoxide or sodium ethoxide, by analogy with a method described by Conrad M. and Zart A., Ber. 1906, 2282-2288.

Alternative methods of preparation of pyrazolidinediones of formula (IV) are:

- Condensation of hydrazines of formula (VI) with malonyl dichloride in a suitable solvent such as THF, by analogy with a method described in WO 02/102359.
- Condensation of N'-acetylhydrazines with malonic acid (i.e. compound of formula (VII), whereby $\text{LG}_1=\text{LG}_2=\text{OH}$), in the presence of phosphorous oxychloride, by analogy with a method described by Michaelis A. and Schenk K., Ber. 1907, 3568-3569.
- Condensation of hydrazines of formula (VI) with 1,2-propadiene-1, 3-dione, by analogy with a method described by van Alphen, Recl. Trav. Chim. Pays-Bas 1924, 823-866.
- Condensation of hydrazines of formula (VI) with ethyl cyanoacetate followed by acid hydrolysis, by analogy with a method described by Weissberger A. and Porter H. D., J. Am. Chem. Soc. 1943, 52-54.

Aldehydes of formula (V) are commercially available or prepared by standard synthetic techniques as hereinafter described in the Examples.

- 5 Particular embodiments of the invention are described in the following Examples, which serve to illustrate the invention in more detail without limiting its scope in any way.

10

Examples

- 15 Temperatures are indicated in degrees Celsius (°C). Unless otherwise indicated, the reactions take place at room temperature.

In mixtures, relations of parts of solvent or eluent or reagent mixtures in liquid form are given as volume relations (v/v), unless indicated otherwise.

20

Abbreviations and acronyms used:

- 25 AcOH: acetic acid, BSA: bovine serum albumin, n-BuLi: n-butyllithium, CH₂Cl₂: dichloromethane, DIPEA: N,N-diisopropylethylamine, DMF: N,N-dimethylformamide, DMSO: dimethyl sulfoxide, EDTA: ethylenediaminetetraacetic acid, Et₃N: triethylamine, EtOAc: ethyl acetate, EtOH: ethanol, g: gram, h: hour, H₂O: water, HCl: hydrochloric acid, HPLC: high-performance liquid chromatography, k: kilo, K₂CO₃: potassium carbonate, l: liter, μ: micro, m: milli, mol: mole, M: molar, MeOH: methanol, Me: methyl, min: minute, 30 MS: mass spectrometry, N: normality of solution, NaCl: sodium chloride, NaHCO₃: sodium hydrogencarbonate, Na₂CO₃: sodium carbonate, NaOH: sodium hydroxyde, Na₂SO₄: sodium sulfate, 10% Pd/C: palladium, 10 weight % on activated carbon, Pd(PPh₃)₂Cl₂: 35 dichlorobis(triphenylphosphine)palladium(II), SDS: sodium dodecylsulfate, THF: tetrahydrofuran, TBAF: tetrabutylammonium fluoride, t_R: retention time.

Analytical HPLC conditions as used in the Examples below:
Analytical HPLC on a Xterra™ MS C₁₈ column (50 x 2.1 mm, 5µm, Waters):

- 5 Linear gradient of water/ 0.06% formic acid (A) and acetonitrile/ 0.06% formic acid (B) from 5% to 95% B over 6 min; flow rate 0.25 ml/min, detection at 215 nm.

Example 1 (R₁ is phenyl)

10

4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione

- A mixture of 1-phenyl-pyrazolidine-3,5-dione (53 mg, 0.30 mmol, prepared according to Conrad M. and Zart A., Ber. 15 1906, 2282-2288) and 2,3-dimethyl-4-propoxybenzaldehyde (87 mg, 0.45 mmol, Example 2b2) in absolute ethanol (4 ml) was heated at reflux for 16 h under inert atmosphere. After cooling to room temperature, the formed precipitate was collected by filtration. The solid was washed with absolute 20 ethanol (3 x 2 ml) and dried in vacuo to give the title compound (80 mg, 76%) as a dark red solid: $t_R = 7.45$ min, MS (positive-ion mode): m/z 351.3 $[M+H]^+$; MS (negative-ion mode): m/z 349.5 $[M-H]^+$.

25 Example 2 (R₁ is phenyl)

- 2a) The following products were prepared by proceeding in a similar manner to the method described in Example 1, but using the listed aldehydes in place of 2,3-dimethyl-4-propoxybenzaldehyde: 30

- 2a1) 4-(4-Methoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-methoxy-3-methylbenzaldehyde (Fluka): $t_R = 6.48$ min, MS (pos.): m/z 309.3 $[M+H]^+$; MS 35 (neg.): m/z 307.5 $[M-H]^+$.

- 2a2) 4-(4-Ethoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-ethoxybenz-aldehyde (Aldrich): $t_R = 6.47$ min, MS (pos.): m/z 309.3 $[M+H]^+$; MS (neg.): m/z 307.5 $[M-H]^+$.
- 5 2a3) 4-(4-Ethoxy-3-methoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-ethoxy-3-methoxybenzaldehyde (Aldrich): $t_R = 6.16$ min, MS (pos.): $(M+H)$ 339.3; MS (neg.): $(M-H)$ 337.5.
- 10 2a4) 4-(2,4-Dimethoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 2,4-dimethoxybenzaldehyde (Aldrich): $t_R = 6.21$ min, MS (pos.): m/z 325.3 $[M+H]^+$; MS (neg.): m/z 323.5 $[M-H]^+$.
- 15 2a5) 4-Naphthalene-2-ylmethylen-1-phenyl-pyrazolidine-3,5-dione, from naphthalene-2-carbaldehyde (Aldrich): $t_R = 6.91$ min, MS (pos.): m/z 315.1 $[M+H]^+$; MS (neg.): m/z 313.3 $[M-H]^+$.
- 20 2a6) 4-(4-tert-Butyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-tert-butyl-benzaldehyde (Fluka): $t_R = 7.35$ min, MS (pos.): m/z 321.4 $[M+H]^+$; MS (neg.): m/z 319.6 $[M-H]^+$.
- 25 2a7) 4-(2,3-Dimethyl-4-methoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 2,3-dimethyl-4-methoxybenzaldehyde (Aldrich): $t_R = 6.78$ min, MS (pos.): m/z 323.1 $[M+H]^+$; MS (neg.): m/z 321.3 $[M-H]^+$.
- 30 2a8) 4-(2,4-Dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 2,4-dimethoxy-3-methylbenzaldehyde (Aldrich): $t_R = 6.67$ min, MS (pos.): m/z 339.1 $[M+H]^+$; MS (neg.): m/z 337.3 $[M-H]^+$.
- 35 2a9) 4-(3-Bromo-4-methoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 3-bromo-4-methoxybenzaldehyde

(Acros): $t_R = 6.48$ min, MS (pos.): m/z 373.3, 375.2 $[M+H]^+$;
MS (neg.): m/z 371.3, 373.4 $[M-H]^+$.

2a10) 1-Phenyl-4-(4-propoxy-benzylidene)-pyrazolidine-3,5-dione, from 4-propoxybenzaldehyde (Aldrich): $t_R = 6.86$ min,
5 MS (pos.): m/z 323.3 $[M+H]^+$; MS (neg.): m/z 321.5 $[M-H]^+$.

2a11) 4-(4-Butoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-butoxybenzaldehyde (Acros): $t_R = 7.21$ min, MS
10 (pos.): m/z 337.4 $[M+H]^+$; MS (neg.): m/z 335.6 $[M-H]^+$.

2a12) 4-(4-Ethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-ethoxy-3-methylbenzaldehyde
(Example 2c): $t_R = 6.86$ min, MS (pos.): m/z 323.4 $[M+H]^+$;
15 MS (neg.): m/z 321.5 $[M-H]^+$.

2a13) 4-(3-Methyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 3-methyl-4-propoxybenzaldehyde
(Example 2d): $t_R = 7.35$ min, MS (pos.): m/z 337.4 $[M+H]^+$;
20 MS (neg.): m/z 335.6 $[M-H]^+$.

2a14) 4-(4-Butoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-butoxy-3-methylbenzaldehyde
(Example 2e): $t_R = 7.82$ min, MS (pos.): m/z 351.2 $[M+H]^+$;
25 MS (neg.): m/z 349.3 $[M-H]^+$.

2a15) 4-(4-Hexyloxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-hexyloxy-3-methylbenzaldehyde (Example 2f): $t_R = 8.53$ min, MS (pos.):
30 m/z 379.2 $[M+H]^+$; MS (neg.): m/z 377.3 $[M-H]^+$.

2a16) 4-(3-Methyl-4-pentyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 3-methyl-4-pentyloxybenzaldehyde (Example 2g): $t_R = 7.98$ min, MS
35 (pos.): m/z 365.4 $[M+H]^+$; MS (neg.): m/z 363.6 $[M-H]^+$.

2a17) 4-(4-Cyclobutylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-cyclobutylmethoxy-3-methylbenzaldehyde (Example 2h): $t_R = 8.02$ min, MS (pos.): m/z 363.1 $[M+H]^+$; MS (neg.): m/z 361.3 $[M-H]^+$.

2a18) 4-[3-Methyl-4-(3-methyl-butoxy)-benzylidene]-1-phenyl-pyrazolidine-3,5-dione, from 3-methyl-4-(3-methylbutoxy)benzaldehyde (Example 2i): $t_R = 8.14$ min, MS (pos.): m/z 365.1 $[M+H]^+$; MS (neg.): m/z 363.3 $[M-H]^+$.

2a19) 4-(4-iso-Butoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-iso-butoxy-3-methylbenzaldehyde (Example 2j): MS (pos.): $t_R = 7.86$ min, m/z 351.1 $[M+H]^+$; MS (neg.): m/z 349.3 $[M-H]^+$.

2a20) 4-[4-(2-Methoxy-ethoxy)-3-methyl-benzylidene]-1-phenyl-pyrazolidine-3,5-dione, from 4-(2-methoxyethoxy)-3-methylbenzaldehyde (Example 2k): $t_R = 6.31$ min, MS (pos.): m/z 353.4 $[M+H]^+$; MS (neg.): m/z 351.5 $[M-H]^+$.

2a21) 4-(3-Chloro-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 3-chloro-4-propoxybenzaldehyde (Example 2l): $t_R = 7.18$ min, MS (pos.): m/z 357.3 $[M+H]^+$; MS (neg.): m/z 355.5 $[M-H]^+$.

2a22) 4-[4-(2-Hydroxy-ethoxy)-3-methyl-benzylidene]-1-phenyl-pyrazolidine-3,5-dione, from 4-(2-hydroxyethoxy)-3-methylbenzaldehyde (Example 2m2): $t_R = 5.57$ min, MS (pos.): m/z 339.4 $[M+H]^+$; MS (neg.): m/z 337.5 $[M-H]^+$.

2a23) 4-(4-Cyclopropylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-cyclopropylmethoxy-3-methyl-benzaldehyde (Example 2n): $t_R = 7.39$ min, MS (pos.): m/z 349.1 $[M+H]^+$; MS (neg.): m/z 347.3 $[M-H]^+$.

2a24) 4-(4-Cyclopentyloxy-2,3-dimethyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 4-cyclopentyloxy-2,3-dimethyl-benzaldehyde (Example 2o): $t_R = 7.79$ min, MS (pos.): m/z 377.4 $[M+H]^+$; MS (neg.): m/z 375.6 $[M-H]^+$.

5

2a25) 1-Phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione, from 4-propoxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde (Example 2p3): $t_R = 7.97$ min, MS (pos.): m/z 377.2 $[M+H]^+$; MS

10 (neg.): m/z 375.4 $[M-H]^+$.

2a26) 4-(2,3-Dimethyl-4-pent-1-ynyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 2,3-dimethyl-4-pent-1-ynyl-benzaldehyde (Example 2q2): $t_R = 7.77$ min, MS (pos.): m/z 359.2 $[M+H]^+$; MS (neg.): m/z 357.3 $[M-H]^+$.

15

2a27) 4-(2,3-Dimethyl-4-pentyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione, from 2,3-dimethyl-4-pentyl-benzaldehyde (Example 2q3): $t_R = 8.10$ min, MS (pos.): m/z 363.3 $[M+H]^+$; MS (neg.): m/z 361.4 $[M-H]^+$.

20

2a28) 1-Phenyl-4-(4-propoxy-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione, from 4-propoxy-1-naphthaldehyde (Example 2r): $t_R = 7.63$ min, MS (pos.): m/z 373.1 $[M+H]^+$; MS (neg.): m/z 371.3 $[M-H]^+$.

25

2b) Aldehydes used in the Examples 1 and 2a12-2a28 were prepared as follows:

30 2b1) 2,3-Dimethyl-4-hydroxybenzaldehyde

A solution of 2,3-dimethyl-4-methoxybenzaldehyde (6.40 g, 40 mmol) in anhydrous CH_2Cl_2 (160 ml) at $-78^\circ C$ was treated with neat boron tribromide (7.56 ml, 80 mmol) dropwise via syringe. The solution was stirred at $-78^\circ C$ for 10 min, warmed to room temperature and stirred for 48 h. The reaction mixture was cooled to $0^\circ C$ and quenched by the addition of water (100 ml). The separated aqueous phase was

35

extracted with CH_2Cl_2 (3 x 100 ml). The combined organic phases were washed with brine (100 ml), dried over Na_2SO_4 , filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound (2.43 g, 40%) as a pale yellow solid: $t_r = 5.15$ min, MS (pos.): m/z 151.2 $[\text{M}+\text{H}]^+$; MS (neg.): m/z 149.3 $[\text{M}-\text{H}]^+$.

10 2b2) 2,3-Dimethyl-4-propoxybenzaldehyde

To a solution of 2,3-dimethyl-4-hydroxy-benzaldehyde (2.43 g, 16.2 mmol), obtained from Example 2b1, in anhydrous DMF (33 ml) was added K_2CO_3 (2.24 g, 24.3 mmol). The mixture was stirred 10 min at room temperature and 1-bromopropane (1.47 ml, 17.8 mmol) was added. The mixture was heated at 50°C overnight. After cooling to room temperature, the mixture was diluted with H_2O (150 ml) and extracted with EtOAc (3 x 100 ml). The combined organic phases were washed with H_2O (100 ml), brine (100 ml), dried over Na_2SO_4 , filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound (2.74 g, 88%) as a white solid: $t_r = 7.24$ min, MS (pos.): m/z 193.3 $[\text{M}+\text{H}]^+$.

25

2c) 4-Ethoxy-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde and bromoethane in place of 1-bromopropane, gave the title compound: $t_r = 6.36$ min, MS (pos.): m/z 165.2 $[\text{M}+\text{H}]^+$.

30

2d) 3-Methyl-4-propoxybenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, gave the title compound: $t_r = 6.89$ min, MS (pos.): m/z 179.3 $[\text{M}+\text{H}]^+$.

35

2e) 4-Butoxy-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and 1-bromobutane in place of 1-bromopropane, gave the title compound: $t_R = 7.42$ min, MS (pos.): m/z 193.2 $[M+H]^+$.

2f) 4-Hexyloxy-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and 1-bromohexane in place of 1-bromopropane, gave the title compound: $t_R = 8.25$ min, MS (pos.): m/z 221.3 $[M+H]^+$.

2g) 4-Pentyloxy-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and 1-bromopentane in place of 1-bromopropane, gave the title compound: $t_R = 7.85$ min, MS (pos.): m/z 207.3 $[M+H]^+$.

2h) 4-Cyclobutylmethoxy-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and bromomethylcyclobutane in place of 1-bromopropane, gave the title compound: $t_R = 7.57$ min, MS (pos.): m/z 205.2 $[M+H]^+$.

2i) 3-Methyl-4-(3-methyl-butoxy)benzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and 1-bromo-3-methylbutane in place of 1-bromopropane, gave the title compound: $t_R = 7.73$ min, MS (pos.): m/z 207.3 $[M+H]^+$.

2j) 4-iso-Butoxy-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and 1-bromo-2-methylpropane in place of 1-bromopropane, gave the title compound: $t_R = 7.38$ min, MS (pos.): m/z 193.2 $[M+H]^+$.

2k) 4-(2-Methoxy-ethoxy)-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and 1-bromo-2-methoxy-ethane in place of 1-bromopropane, gave the title compound: $t_R = 5.71$ min, MS (pos.): m/z 195.2 $[M+H]^+$.

2l) 3-Chloro-4-propoxybenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-chlorobenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, gave the title compound: $t_R = 6.80$ min, MS (pos.): m/z 199.2 $[M+H]^+$.

2m1) 4-[2-(tert-Butyl-dimethylsilanyloxy)-ethoxy]-3-methylbenzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and (2-bromomethoxy)-tert-butyl-dimethylsilane in place of 1-bromopropane, gave the title compound: $t_R = 8.39$ min, MS (pos.): m/z 295.3 $[M+H]^+$.

2m2) 4-(2-Hydroxyethoxy)-3-methylbenzaldehyde

To a solution of 4-[2-(tert-butyl-dimethylsilanyloxy)-ethoxy]-3-methylbenzaldehyde (500 mg, 1.70 mmol), obtained from Example 2m1, and AcOH (60 μ l, 1.0 mmol) in THF (5 ml) was added dropwise a 1N solution of TBAF (2 ml, 2 mmol) in THF. The reaction mixture was stirred overnight at room temperature. The mixture was then diluted with H_2O (20 ml) and extracted with EtOAc (3 x 20 ml). The combined organic

phases were washed with H₂O (20 ml), brine (20 ml), dried over Na₂SO₄, filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound as colorless oil (259 mg, 85%): t_R = 4.68 min, MS (pos.): m/z 181.2 [M+H]⁺.

2n) 4-Cyclopropylmethoxy-3-methyl-benzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-3-methylbenzaldehyde in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, and (bromomethyl)cyclopropane in place of 1-bromopropane, gave the title compound: t_R = 6.89 min, MS (pos.): m/z 191.2 [M+H]⁺.

2o) 4-Cyclopentyloxy-2,3-dimethyl-benzaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using cyclopentyl bromide in place of 1-bromopropane, gave the title compound: t_R = 7.68 min, MS (pos.): m/z 219.6 [M+H]⁺.

2p1) 5-Propoxy-1,2,3,4-tetrahydro-naphthalene

Proceeding in a similar manner to the method described in Example 2b2, but using 5, 6, 7, 8-tetrahydronaphtalen-1-ol in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, gave the title compound: t_R = 8.40 min, MS (pos.): m/z 191.4 [M+H]⁺.

2p2) 5-Bromo-8-propoxy-1,2,3,4-tetrahydro-naphthalene

To a stirred solution of 5-propoxy-1,2,3,4-tetrahydro-naphthalene (1.14 g, 6 mmol), obtained from Example 2p1, in acetonitrile (30 ml) was added N-bromosuccinimide (1.17 g, 6.6 mmol). The reaction mixture was stirred at room temperature for 2 h. The solvent was then evaporated under reduced pressure and water (20 ml) was added to the resulting residue. The aqueous solution was then extracted with EtOAc (3 x 25 ml). The combined organic phases were washed with H₂O (20 ml), brine (20 ml), dried over Na₂SO₄,

filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound as colorless oil (1.60 g, 99%): $t_R = 9.02$ min.

5

2p3) 4-Propoxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde

To solution of 5-bromo-8-propoxy-1,2,3,4-tetrahydro-naphthalene (1.60 g, 5.9 mmol), obtained from Example 2p2, in THF (12.9 ml) at -78°C was added dropwise in 5 min a 1.6N solution of *n*-BuLi in hexanes (4.4 ml, 7.1 mmol). The reaction mixture was stirred at -78°C for 5 min and DMF (2.5 ml, 32.2 mmol) was then added. After warming to room temperature in 30 min and stirring at this temperature for 30 min, the reaction mixture was diluted with water (20 ml) and extracted with EtOAc (3 x 50 ml). The combined organic phases were washed with brine (50 ml), dried over Na_2SO_4 , filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound as pale yellow oil (800 mg, 57%): $t_R = 7.81$ min, MS (pos.): m/z 219.1 $[\text{M}+\text{H}]^+$.

25 2q1) 2,3-Dimethyl-4-trifluoromethanesulfonyloxybenzaldehyde
A mixture of 2,3-dimethyl-4-hydroxybenzaldehyde (1 g, 6.7 mmol), obtained from Example 2b1, *N*-phenylbis(trifluoromethanesulphonimide) (2.38 g, 6.7 mmol) and DIPEA (1.14 ml, 6.7 mmol) in CH_2Cl_2 (10 ml) was stirred overnight at room temperature. The reaction mixture was diluted with CH_2Cl_2 (50 ml). The resulting organic phase was successively washed with saturated aqueous NaHCO_3 (2 x 30 ml) and brine (30 ml), dried over MgSO_4 , filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound as colorless oil (1.50 g, 80%): $t_R = 7.09$ min, MS (pos.): m/z 283.0 $[\text{M}+\text{H}]^+$.

2q2) 2,3-Dimethyl-4-pent-1-ynyl-benzaldehyde

To a degassed solution containing $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (362 mg, 0.52 mmol), copper iodide (98 mg, 0.52 mmol), 2,3-dimethyl-4-trifluoromethanesulfonyloxybenzaldehyde (1.47 g, 5.2 mmol),
5 obtained from Example 2q1, and DIPEA (2.83 ml, 16.5 mmol) in DMF (5 ml), was added 1-pentyne (1.02 ml, 10.3 mmol). After 24 h at room temperature, the reaction mixture was poured into water (50 ml) and extracted with EtOAc (2 x 50 ml). The combined organic phases were washed with brine (50 ml), dried over MgSO_4 , filtered and concentrated. The
10 resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound as pale yellow oil (971 mg, 94%): $t_R = 7.78$ min, MS (pos.): m/z 201.4 $[\text{M}+\text{H}]^+$.
15

2q3) 2,3-Dimethyl-4-pentyl-benzaldehyde

A mixture of 2,3-dimethyl-4-pent-1-ynyl-benzaldehyde (300 mg, 1.50 mmol), obtained from Example 2q2, and 10% Pd/C (45 mg) in EtOAc (4 ml) was stirred for 1 h 30 under hydrogen
20 at room temperature. After filtration on a Celite pad, which was washed with EtOAc, the filtrate was concentrated in vacuo to yield the title compound as colorless oil (285 mg, 93%): $t_R = 8.12$ min, MS (pos.): m/z 205.4 $[\text{M}+\text{H}]^+$.
25

2r) 4-Propoxy-1-naphtaldehyde

Proceeding in a similar manner to the method described in Example 2b2, but using 4-hydroxy-1-naphtaldehyde (Aldrich) in place of 2,3-dimethyl-4-hydroxy-benzaldehyde, gave the
30 title compound: $t_R = 7.38$ min, MS (pos.): m/z 215.3 $[\text{M}+\text{H}]^+$.

Example 3 (R_1 is 4-Ethoxycarbonylphenyl)

3a) The following products were prepared by proceeding in a
35 similar manner to the method described in Example 1, but using ethyl 4-(3,5-dioxo-pyrazolidin-1-yl)-benzoate

(Example 3b2) in place of 1-phenyl-pyrazolidine-3,5-dione and the listed aldehydes:

5 3a1) Ethyl 4-(4-benzylidene-3,5-dioxo-pyrazolidin-1-yl)-benzoate, from benzaldehyde (Fluka): $t_R = 6.73$ min, MS (pos.): m/z 337.3 $[M+H]^+$; MS (neg.): m/z 335.5 $[M-H]^+$.

10 3a2) Ethyl 4-[4-(2-hydroxy-3-methoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzoate, from 2-hydroxy-3-methoxybenzaldehyde (Acros): $t_R = 6.34$ min, MS (pos.): m/z 383.3 $[M+H]^+$; MS (neg.): m/z 381.5 $[M-H]^+$.

15 3a3) Ethyl 4-[4-(2-methoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzoate, from 2-methoxybenzaldehyde (Acros): $t_R = 6.77$ min, MS (pos.): m/z 367.3 $[M+H]^+$; MS (neg.): m/z 365.5 $[M-H]^+$.

20 3a4) Ethyl 4-[4-(3-methoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzoate, from 3-methoxybenzaldehyde (Acros): MS (pos.): $t_R = 6.84$ min, m/z 367.3 $[M+H]^+$; MS (neg.): m/z 365.5 $[M-H]^+$.

25 3a5) Ethyl 4-(3,5-dioxo-4-pyridin-3-ylmethylene-pyrazolidin-1-yl)-benzoate, from 3-pyridinecarboxaldehyde (Acros): $t_R = 5.64$ min, MS (pos.): m/z 338.5 $[M+H]^+$; MS (neg.): m/z 336.5 $[M-H]^+$.

30 3a6) Ethyl 4-(3,5-dioxo-4-thiophen-3-ylmethylene-pyrazolidin-1-yl)-benzoate, from 3-thiophencarboxaldehyde (Aldrich): $t_R = 6.59$ min, MS (pos.): m/z 343.3 $[M+H]^+$; MS (neg.): m/z 341.4 $[M-H]^+$.

35 3a7) Ethyl 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzoate, from 2, 3-dimethyl-4-propoxybenzaldehyde (Example 2b2): $t_R = 7.89$ min, MS (pos.): m/z 423.4 $[M+H]^+$; MS (neg.): m/z 421.6 $[M-H]^+$.

3b) Ethyl 4-(3,5-dioxo-pyrazolidin-1-yl)-benzoate used in Examples 3a1-3a7 was prepared as following:

3b1) Ethyl 4-[N'-(2-ethoxycarbonyl-acetyl)-hydrazino]-benzoate

(4-Hydrazino)ethylbenzoate hydrochloride (12 g, 551.4 mmol, prepared according to Coquet G. et al., Tetrahedron 2000, 56, 2975-2984) was stirred for 15 min at room temperature in a mixture of 10% aqueous Na_2CO_3 solution (100 ml) and CH_2Cl_2 (200 ml). The separated aqueous solution was extracted with CH_2Cl_2 (3 x 200 ml). The combined organic phases were dried over Na_2SO_4 , filtered and concentrated. The residue was dissolved in anhydrous THF (100 ml) and Et_3N (8.11 mL, 58.3 mmol) was added. The reaction mixture was cooled to -10°C and a solution of ethyl malonyl chloride (7.12 ml, 56.6 mmol) in anhydrous THF (50 ml) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with H_2O (100 ml) and extracted with EtOAc (3 x 100 ml). The combined organic phases were washed with H_2O (100 ml), brine (100 ml), dried over Na_2SO_4 , filtered and concentrated to yield crude title compound as a brown residue (16.3 g): $t_R = 5.34$ min, MS (pos.): m/z 295.1 $[\text{M}+\text{H}]^+$; MS (neg.): m/z 293.3 $[\text{M}-\text{H}]^+$.

3b2) Ethyl 4-(3,5-dioxo-pyrazolidin-1-yl)-benzoate

Crude ethyl 4-[N'-(2-ethoxycarbonyl-acetyl)-hydrazino]-benzoate (16.3 g), obtained from Example 3b1, was dissolved in EtOH (100 ml) and an ethanolic 1N NaOH solution (110 ml, 110 mmol) was added. The reaction mixture was stirred 30 min at room temperature. The reaction mixture was then acidified by addition of aqueous 1N HCl . The precipitate formed was collected by filtration, washed with H_2O (3 x 20 ml), dried on the sintered glass and in vacuo to yield the title compound as an off-white solid (8.27 g, 60%): $t_R = 4.50$ min, MS (pos.): m/z 249.2 $[\text{M}+\text{H}]^+$; MS (neg.): m/z 247.3 $[\text{M}-\text{H}]^+$.

Example 4 (R₁ is 2-Pyridyl)

4a) The following products were prepared by proceeding in a similar manner to the method described in Example 1, but using 1-pyridin-2-yl-pyrazolidine-3,5-dione (Example 4b2) in place of 1-phenyl-pyrazolidine-3,5-dione, and the listed aldehydes:

4a1) 4-(3-Methyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione, from 3-methyl-4-propoxybenzaldehyde (Example 2d): $t_R = 7.30$ min, MS (pos.): m/z 338.3 $[M+H]^+$; MS (neg.): m/z 336.3 $[M-H]^+$.

4a2) 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione, from 2, 3-dimethyl-4-propoxybenzaldehyde (Example 2b2): $t_R = 7.44$ min, MS (pos.): m/z 352.2 $[M+H]^+$; MS (neg.): m/z 350.3 $[M-H]^+$.

4b) 1-Pyridin-2-yl-pyrazolidine-3,5-dione used in Examples 4a1-4a2 was prepared as follows:

4b1) Ethyl (N'-pyridin-2-yl-hydrazinocarbonyl)-acetate

To a solution of 2-hydrazinopyridine (2.0 g, 18.3 mmol) and Et₃N (2.68 ml, 19.2 mmol) in anhydrous THF (30 ml) cooled at -10°C was added dropwise ethyl malonyl chloride (2.35 ml, 18.7 mmol). The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with H₂O (20 ml) and extracted with EtOAc (2 x 20 ml). The combined organic phases were washed with brine (20 ml), dried over Na₂SO₄, filtered and concentrated. The resulting residue was purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound (2.11g, 52%) as a brown solid: $t_R = 0.98$ min, MS (pos.): m/z 224.5 $[M+H]^+$; MS (neg.): m/z 222.5 $[M-H]^+$.

4b2) 1-Pyridin-2-yl-pyrazolidine-3,5-dione

Ethyl (*N'*-pyridin-2-yl-hydrazinocarbonyl)-acetate (1.0 g, 4.48 mmol), obtained from Example 4b1, was dissolved in a 1N ethanolic NaOH solution (9 ml, 9 mmol). The reaction mixture was stirred 30 min at room temperature, acidified by addition of AcOH, then diluted with H₂O (20 ml) and extracted with CH₂Cl₂ (2 x 30 ml). The combined organic phases were washed with H₂O (30 ml), dried over Na₂SO₄, filtered and concentrated to yield the title compound (500 mg, 63%) as a yellow solid: *t_R* = 2.26 min, MS (pos.): *m/z* 178.2 [M+H]⁺; MS (neg.): *m/z* 176.3 [M-H]⁺.

Example 5 (*R₁* is 4-Bromophenyl)

5a) 1-(4-Bromo-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione Proceeding in a similar manner to the method described in Example 1, but using 1-(4-bromo-phenyl)-pyrazolidine-3,5-dione (Example 5b) in place of 1-phenyl-pyrazolidine-3,5-dione, gave the title compound: *t_R* = 7.95 min, MS (pos.): *m/z* 429.3, 431.2 [M+H]⁺; MS (neg.): *m/z* 427.5, 429.4 [M-H]⁺.

5b) 1-(4-Bromo-phenyl)-pyrazolidine-3,5-dione used in Example 5a was prepared as follows:

5b1) Ethyl [*N'*-(4-bromo-phenyl)-hydrazinocarbonyl]-acetate Proceeding in a similar manner to the method described in Example 4b1, but using 4-bromophenylhydrazine hydrochloride in place of 2-hydrazinopyridine, gave the title compound: *t_R* = 5.53 min, MS (pos.): *m/z* 301.0, 303.1 [M+H]⁺; MS (neg.): *m/z* 299.1, 301.2 [M-H]⁺.

5b2) 1-(4-Bromo-phenyl)-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 3b2, but using ethyl [*N'*-(4-bromo-phenyl)-hydrazinocarbonyl]-acetate, obtained from Example 5b1, instead of ethyl 4-[*N'*-(2-ethoxycarbonyl-acetyl)-

hydrazino]-benzoate, gave the title: MS (pos.): m/z 255.3, 257.3 [M+H]⁺; MS (neg.): m/z 253.4, 255.4 [M-H]⁺.

Example 6 (R₁ is 4-Methoxyphenyl)

5 6a) 1-(4-Methoxy-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 1, but using 1-(4-methoxy-phenyl)-pyrazolidine-3,5-dione (Example 6b) in place of 1-phenyl-pyrazolidine-3,5-dione, gave the title compound: t_R = 7.22 min, MS (pos.): m/z 381.4 [M+H]⁺; MS (neg.): m/z 379.6 [M-H]⁺.

6b) 1-(4-Methoxy-phenyl)-pyrazolidine-3,5-dione used in Example 6a was prepared as follows:

6b1) Ethyl [N'-(4-methoxy-phenyl)-hydrazinocarbonyl]-acetate

Proceeding in a similar manner to the method described in Example 4b1, but using 4-methoxyphenylhydrazine hydrochloride in place of 2-hydrazinopyridine, gave the title compound: MS (pos.): m/z 253.1 [M+H]⁺.

6b2) 1-(4-Methoxy-phenyl)-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 4b2, but using ethyl [N'-(4-methoxy-phenyl)-hydrazinocarbonyl]-acetate, obtained from Example 6b1, instead of ethyl (N'-pyridin-2-yl-hydrazinocarbonyl)-acetate, gave the title compound: t_R = 3.85 min, MS (pos.): m/z 206.9 [M+H]⁺.

Example 7 (R₁ is 4-Cyanophenyl)

7a) 4-[4-(2,3-Dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzonitrile

Proceeding in a similar manner to the method described in Example 1, but using 4-(3,5-dioxo-pyrazolidin-1-yl)-

benzonitrile (Example 7b) in place of 1-phenyl-pyrazolidine-3,5-dione, gave the title compound: $t_R = 7.58$ min, MS (pos.): m/z 376.4 $[M+H]^+$; MS (neg.): m/z 374.6 $[M-H]^+$.

5

7b) 4-(3,5-Dioxo-pyrazolidin-1-yl)-benzonitrile used in Example 7a was prepared as follows:

7b1) Ethyl $[N'-(4\text{-cyano-phenyl})\text{-hydrazinocarbonyl}]\text{-acetate}$

10 Proceeding in a similar manner to the method described in Example 4b1, but using 4-cyanophenylhydrazine hydrochloride in place of 2-hydrazinopyridine, gave the title compound: $t_R = 4.67$ min, MS (pos.): m/z 247.8 $[M+H]^+$; MS (neg.): m/z 245.9 $[M-H]^+$.

15

7b2) 4-(3,5-Dioxo-pyrazolidin-1-yl)-benzonitrile

Proceeding in a similar manner to the method described in Example 4b2, but using ethyl $[N'-(4\text{-cyano-phenyl})\text{-hydrazinocarbonyl}]\text{-acetate}$, obtained from Example 7b1, instead of ethyl $(N'\text{-pyridin-2-yl-hydrazinocarbonyl})\text{-acetate}$, gave the title compound: $t_R = 4.17$ min, MS (pos.): m/z 201.9 $[M+H]^+$; MS (neg.): m/z 199.9 $[M-H]^+$.

20

Example 8 (R_1 is 4-Fluorophenyl)

25

8a) 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 1, but using 1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione (Example 8b) in place of 1-phenyl-pyrazolidine-3,5-dione, gave the title compound: $t_R = 7.51$ min, MS (pos.): m/z 369.4 $[M+H]^+$; MS (neg.): m/z 367.6 $[M-H]^+$.

30

8b) 1-(4-Fluoro-phenyl)-pyrazolidine-3,5-dione used in Example 8a was prepared as follows:

35

8b1) Ethyl $[N'-(4\text{-fluoro-phenyl})\text{-hydrazinocarbonyl}]\text{-acetate}$

Proceeding in a similar manner to the method described in Example 4b1, but using 4-fluorophenylhydrazine hydrochloride in place of 2-hydrazinopyridine, gave the title compound: $t_R = 4.55$ min, MS (neg.): m/z 238.9 $[M-H]^+$.

5

8b2) 1-(4-Fluoro-phenyl)-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 4b2, but using ethyl $[N'-(4\text{-fluoro-phenyl})\text{-hydrazinocarbonyl}]\text{-acetate}$, obtained from Example 8b1, instead of ethyl $(N'\text{-pyridin-2-yl-hydrazinocarbonyl})\text{-acetate}$, gave the title compound: $t_R = 3.93$ min, MS (pos.): m/z 195.0 $[M+H]^+$; MS (neg.): m/z 193.0 $[M-H]^+$.

10

Example 9 (R_1 is 4-Methylphenyl)

15

9a) 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-(4-methyl-phenyl)-pyrazolidine-3,5-dione

20

Proceeding in a similar manner to the method described in Example 1, but using 1-(4-methyl-phenyl)-pyrazolidine-3,5-dione (Example 9b) in place of 1-phenyl-pyrazolidine-3,5-dione, gave the title compound: $t_R = 7.65$ min, MS (pos.): m/z 365.4 $[M+H]^+$; MS (neg.): m/z 363.6 $[M-H]^+$.

25

9b) 1-(4-Methyl-phenyl)-pyrazolidine-3,5-dione used in Example 9a was prepared as follows:

9b1) Ethyl $[N'-(4\text{-methyl-phenyl})\text{-hydrazinocarbonyl}]\text{-acetate}$

30

Proceeding in a similar manner to the method described in Example 4b1, but using 4-methylphenylhydrazine hydrochloride in place of 2-hydrazinopyridine, gave the title compound: $t_R = 5.18$ min, MS (neg.): m/z 235.0 $[M-H]^+$.

9b2) 1-(4-Methyl-phenyl)-pyrazolidine-3,5-dione

35

Proceeding in a similar manner to the method described in Example 4b2, but using ethyl $[N'-(4\text{-methyl-phenyl})\text{-hydrazinocarbonyl}]\text{-acetate}$, obtained from Example 9b1,

instead of ethyl (*N'*-pyridin-2-yl-hydrazinocarbonyl)-acetate, gave the title compound: $t_R = 4.34$ min, MS (pos.): m/z 190.8 $[M+H]^+$; MS (neg.): m/z 188.9 $[M-H]^+$.

5 Example 10 (R_1 is 2-Chlorophenyl)

10a) 1-(2-Chloro-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione

10 A mixture of 1-(2-chloro-phenyl)-pyrazolidine-3,5-dione (64 mg, 0.3 mmol, Example 10b) and 2,3-dimethyl-4-propoxybenzaldehyde (87 mg, 0.45 mmol, Example 2b2) in absolute ethanol (4 ml) was heated at reflux for 16 h under inert atmosphere. After cooling to room temperature, the solvent was evaporated in vacuo. The resulting residue was
15 purified by flash chromatography on silica gel using a gradient of EtOAc in heptane as eluent to yield the title compound (62 mg, 54%) as an orange-red solid: $t_R = 7.16$ min, MS (pos.): m/z 385.4 $[M+H]^+$; MS (neg.): m/z 383.5 $[M-H]^+$.

20 10b) 1-(2-Chloro-phenyl)-pyrazolidine-3,5-dione

To a solution of sodium ethoxide (42 mmol) in absolute ethanol (22 ml) were added diethylmalonate (2.12 ml, 14.0 mmol) and 2-chlorophenylhydrazine hydrochloride (2.5 g, 14.0 mmol). The volatiles were immediately distilled at
25 atmospheric pressure and the resulting residue was further heated at 140°C to dryness. After cooling to room temperature, the residue was dissolved in water (50 ml). Neutral was removed from the aqueous solution by extraction
30 with diethyl ether (2 x 100 ml). The aqueous phase was then acidified to pH 1 by addition of 1N aqueous HCl and extracted with EtOAc (3 x 100 ml). The combined organic phases were washed with H₂O (50 ml), brine (50 ml), dried over MgSO₄, filtered and concentrated. The resulting
35 residue was purified by flash chromatography on silica gel using a gradient of MeOH in CH₂Cl₂ as eluent to yield the title compound (500 mg, 17%) as a pale brown solid: $t_R =$

benzaldehyde (Example 2o): $t_R = 6.29$ min, MS (pos.): m/z 301.5 $[M+H]^+$; MS (neg.): m/z 299.6 $[M-H]^+$.

- 5 12a3) 4-(4-Propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione, from 4-propoxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde (Example 2p3): $t_R = 6.36$ min, MS (pos.): m/z 301.2 $[M+H]^+$; MS (neg.): m/z 299.3 $[M-H]^+$.
- 10 12a4) 4-(2,3-Dimethyl-4-pent-1-ynyl-benzylidene)-pyrazolidine-3,5-dione, from 2,3-dimethyl-4-pent-1-ynyl-benzaldehyde (Example 2q2): $t_R = 6.32$ min, MS (pos.): m/z 283.2 $[M+H]^+$; MS (neg.): m/z 281.3 $[M-H]^+$.
- 15 12a5) 4-(2,3-Dimethyl-4-pentyl-benzylidene)-pyrazolidine-3,5-dione, from 2,3-dimethyl-4-pentyl-benzaldehyde (Example 2q3): $t_R = 6.64$ min, MS (pos.): m/z 287.2 $[M+H]^+$; MS (neg.): m/z 285.3 $[M-H]^+$.
- 20 12a6) 4-(4-Propoxy-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione, from 4-propoxy-1-naphthaldehyde (Example 2r): $t_R = 6.13$ min, MS (pos.): m/z 297.2 $[M+H]^+$; MS (neg.): m/z 295.3 $[M-H]^+$.

25 Example 13 (R_1 is Methyl)

- 13a) 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-methyl-pyrazolidine-3,5-dione
Proceeding in a similar manner to the method described in
30 Example 1, but using 1-methyl-pyrazolidine-3,5-dione (Example 13b) in place of 1-phenyl-pyrazolidine-3,5-dione, gave the title compound: $t_R = 6.15$ min, MS (pos.): m/z 289.5 $[M+H]^+$; MS (neg.): m/z 287.5 $[M-H]^+$.

- 35 13b) 1-Methyl-pyrazolidine-3,5-dione
Proceeding in a similar manner to the method described in Example 10b, but using methylhydrazine in place of 2-

chlorophenylhydrazine hydrochloride, gave the title compound: $t_R = 0.93$ min, MS (pos.): m/z 115.2 $[M+H]^+$; MS (neg.): m/z 113.3 $[M-H]^+$.

5 Example 14 (R_1 is 4-Pyridyl)

14a) 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-pyridin-4-yl-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 10a, but using 1-pyridin-4-yl-pyrazolidine-3,5-dione (Example 14b) in place of 1-(2-chloro-phenyl)-pyrazolidine-3,5-dione, gave the title compound: $t_R = 5.56$ min, MS (pos.): m/z 352.5 $[M+H]^+$; MS (neg.): m/z 350.6 $[M-H]^+$.

15 14b) 1-Pyridin-4-yl-pyrazolidine-3,5-dione

Proceeding in a similar manner to the method described in Example 10b, but using 4-pyridylhydrazine hydrochloride (prepared according to F. G. Mann et al., J. Chem. Soc. 1959, 3830-3834) in place of 2-chlorophenylhydrazine hydrochloride, gave the title compound: $t_R = 0.93$ min, MS (neg.): m/z 176.4 $[M-H]^+$.

Example 15: P2Y₁₂ receptor binding assay










25 Chinese Hamster Ovary (CHO) cells with recombinant expression of the human P2Y₁₂ receptor were cultured in 24 well cell-culture plates. Cells were washed three times with binding buffer (50 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.5 %BSA). The cells were then incubated with 0.5 ml per well binding buffer containing tritium-labeled 2-methyl-thio-adenosine 5'-diphosphate (2-methyl-S-ADP) (between 100'000 and 300'000 dpm per well) and various concentrations of test compounds. After incubation at room temperature for 2 hours, cells were washed three times with binding buffer. Then, cells were solubilized by addition of 0.5 ml solubilization buffer (SDS, NaOH, EDTA). The

















content of each well was then transferred into beta-counter vials and 2.0 ml of Ultima Gold Scintillation liquid was added. After quantification of the cell-associated signal, extent of inhibition was calculated relative to maximal possible inhibition demonstrated by addition of excess of cold 2-methyl-S-ADP.

















Example 16: Test for antagonist binding to the platelet ADP receptor P2Y₁₂.













10

The test is conducted as described hereinabove. Exemplary IC₅₀ values are given below.

Structure	Example	IC50 (μM)
	1	0.024
	2a1	2.7
	2a2	3.1
	2a3	6.3
	2a4	6.7
	2a5	9.1
	2a6	2.3
	2a7	0.19
	2a8	0.11

	2a9	3.1
	2a10	1.9
	2a11	1.3
	2a12	0.47
	2a13	0.32
	2a14	0.3
	2a15	0.78
	2a16	0.2
	2a17	1.3
	2a18	1.8
	2a19	1.2
	2a20	3.9
	2a21	3.2
	2a22	5.3
	2a23	0.2
	2a24	1.52

	2a25	0.03
	2a26	0.23
	2a27	0.85
	2a28	0.1
	3a1	6.4
	3a2	9.5
	3a3	7.2
	3a4	5.7
	3a5	2.8
	3a6	6.4
	3a7	6.7
	4a1	1.3
	4a2	0.14
	5a	2.9
	6a	2.1
	7a	0.31

	8a	0.083
	9a	1.3
	10a	0.99
	11a	3.33
	12a1	0.17
	12a2	1.5
	12a3	0.055
	12a4	1
	12a5	0.91
	12a6	0.25
	13a	3.46
	14a	1.06

Example 17: ADP induced Platelet Aggregation

17a) Preparation of platelet-rich plasma (PRP)

After obtaining informed consent, blood was obtained by
5 vein puncture from healthy volunteers using trisodium
citrate, at 108 mM final concentration, as the
anticoagulant. Platelet-rich plasma (PRP) was separated by
centrifugation at 20°C. for 10 minutes at 160 g. Part of
the blood was centrifuged for 10 minutes at 5000 g to yield
10 platelet poor plasma (PPP).

17b) ADP induced Platelet Aggregation

Platelet aggregation was measured in a Chronolog
lumiaggregometer with stirring (900 rpm) at 37°C. PRP was
15 placed into the cuvette and allowed to equilibrate at 37°C
for two min. In a first phase, the ADP concentration to
give optimal extent of aggregation was determined for the
PRP of each donor. In a second phase, PRP was incubated
with inhibitors for 2 min at 37°C prior to the addition of
20 the agonist ADP at 1-5 μ M final concentration.
The change in light absorbance, indicative of ongoing
aggregation, was monitored during 5 min. The extent of
platelet aggregation was calculated relative to light
absorbance of PRP (not aggregated) and PPP (full
25 aggregation).

Example 18: Functional assay (FLIPR)

Chinese Hamster Ovary (CHO) cells stably expressing the
30 human P2Y₁₂ receptor under the control of the
cytomegalovirus promoter in the expression vector pcDNA3
(Invitrogen) were grown to near confluency in Ham's F-12
medium supplemented with 10% fetal calf serum (both
Bioconcept, Switzerland) under standard mammalian cell
35 culture conditions (37°C and 5% carbon dioxide). Cells were
treated with 0.02% EDTA in phosphate buffer saline (PBS,
Gibco) for 10 min, detached by tapping, and collected by

centrifugation for five minutes at 200 g, all at room temperature. They were incubated one hour stirring at 37°C and 5% CO₂ with 4 µM Fluo-3, 0.04% Pluronic F-127 (both Molecular Probes), 5 mM probenecid (Sigma), 20 mM HEPES (Gibco) in assay buffer (equal parts of Hank's BSS (HBSS, Bioconcept) and Ham's F-12). They were then washed with and resuspended in assay buffer. 50,000 cells in 60 µl were transferred to each well of a 384-well FLIPR assay plate (Greiner) and sedimented by centrifugation. A FLIPR384 instrument (Molecular Devices) was operated following the manufacturer's standard instructions, adding 10 µl of compound dissolved at 10 mM in DMSO and diluted prior to the experiment in assay buffer to obtain the desired final concentration. 10 µl of ADP (Sigma) solution in assay buffer supplemented with bovine serum albumin (fatty acid content <0.02%, Sigma) was then added to obtain a final concentration of 3 µM and 0.1%, respectively. Fluorescence emission was recorded during both additions.

20 Example 19: Gelatin solution

A sterile-filtered aqueous solution, with 2% cyclodextrins as solubilisers, of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 8a) as active ingredient, is so mixed under aseptic conditions, with heating, with a sterile gelatin solution containing phenol as preservative, that 1.0 ml of solution has the following composition:

30 active ingredient	3 mg
gelatin	150.0 mg
phenol	4.7 mg
dist. water with 20% cyclodextrins	
as solubilisers	1.0 ml

35

Example 20: Sterile dry substance for injection

5 mg of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 12a1) as active ingredient are dissolved in 1 ml of an aqueous solution with 20 mg of mannitol and 20% cyclodextrins as solubilisers. The solution is sterile-filtered and introduced under aseptic conditions into a 2 ml ampoule, deep-frozen and lyophilized. Before use, the lyophilisate is dissolved in 1ml of distilled water or 1 ml of physiological saline solution. The solution is administered intramuscularly or intravenously. This formulation can also be introduced into a twin-chambered injection ampoule.

Example 21: Film-coated tablets

The following ingredients are used for the preparation of 10,000 tablets each containing 100 mg of active ingredient:

active ingredient	1000 g
corn starch	680 g
colloidal silica	200 g
magnesium stearate	20 g
stearic acid	50 g
sodium carboxymethyl starch	250 g
water	quantum satis

A mixture of one of the compounds of formula (III) mentioned in the preceding Examples (e.g. Example 4a2) as active ingredient, 50 g of corn starch and the colloidal silica is processed with a starch paste, made from 250 g of corn starch and 2.2 kg of demineralised water, to form a moist mass. This is forced through a sieve having a mesh size of 3 mm and dried at 45°C for 30 min in a fluidized bed drier. The dry granulates are pressed through a sieve having a mesh size of 1 mm, mixed with a pre-sieved mixture (1 mm sieve) of 330 g of corn starch, the magnesium stearate, the stearic acid and the sodium carboxymethyl starch, and compressed to form slightly biconvex tablets.

Example 22: Soft capsules

5000 soft gelatin capsules, each comprising as active
ingredient 0.05 g of one of the compounds of formula (III)
5 mentioned in the preceding Examples are prepared as
follows:


active ingredient 250 g
lauroglycol® 2 liters

10

The pulverized active ingredient is suspended in
Lauroglykol® (propylene glycol laureate, Glattefossé S. A.,
Saint Priest, France) and ground in a wet pulverizer to
produce a particle size of about 1 to 3 μm . 0.42 g portions
15 of the mixture are then introduced into soft gelatin
capsules using a capsule-filling machine.

Claims

1. The use of pyrazolidinedione derivatives of the
5 general formula



wherein

- 10 R₁ is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; and R₂ is aryl or heteroaryl;
tautomers thereof;
geometric isomers thereof and tautomers of these geometric
15 isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof;
pharmaceutically acceptable acid addition salts of compounds which are basic;
20 pharmaceutically acceptable salts of compounds containing acidic groups with bases;
pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups;
prodrugs of compounds in which a prodrug forming group is
25 present; as well as hydrates or solvates thereof;
as platelet adenosine diphosphate receptor antagonists for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated
30 with platelet aggregation and, respectively, for the manufacture of corresponding medicaments.

2. The use according to claim 1 wherein the disease or condition is thrombosis.

3. The use according to claim 1 or 2 wherein R_1 is hydrogen, alkyl, aryl or heteroaryl.


4. The use according to claim 3 wherein R_1 is hydrogen, alkyl, phenyl, bromophenyl, chlorophenyl, fluorophenyl, methylphenyl, methoxyphenyl, cyanophenyl, alkoxy carbonylphenyl or pyridinyl.

5. The use according to claim 4 wherein R_1 is hydrogen, methyl, phenyl, 2-pyridinyl, 4-pyridinyl, 2-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 2-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 4-cyanophenyl or 4-ethoxycarbonylphenyl.

6. The use according to any one of claims 1 to 5 wherein R_2 is naphthalen-2-yl, thienyl or pyridyl.

7. The use according to claim 6 wherein R_2 is naphthalen-2-yl, pyridin-3-yl or thiophen-3-yl.

8. The use according to claims 1 or 2 of compounds of the general formula



(III)

including their geometric isomers and tautomers and mixtures thereof as well as their salts, esters and prodrugs mentioned in claim 1, wherein R_1 is as defined in any one of claims 1 and 3 to 5;

R₃ is hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy; and

5 R₄ and R₅, each independently of the other, are hydrogen, halogen, hydroxy, alkyl or alkoxy, or, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system.

10 9. The use according to claim 8 wherein R₃ and R₅ each are hydrogen and R₄ is alkoxy; or R₃ and R₄ each are hydrogen and R₅ is alkoxy; or R₃ is hydrogen, R₄ is alkoxy, and R₅ is hydroxy.

15 10. The use according to claim 8 wherein the alkoxy group is methoxy.

20 11. The use according to claim 8 wherein R₃ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy and R₄ and R₅ both are hydrogen, or R₄ is halogen, alkyl or alkoxy and R₅ is hydrogen, or R₄ and R₅ each independently are alkyl or alkoxy.

25 12. The use according to claim 11 wherein R₃ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, 30 cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, 2-methoxy-ethoxy, and R₄ and R₅ both are hydrogen or R₄ is chloro, bromo, methyl or methoxy and R₅ is hydrogen, or R₄ and R₅ each independently are methyl or methoxy.

35 13. The use according to claim 8 wherein R₃ is hydrogen or alkoxy and R₄ and R₅ together with the phenyl ring to which they are attached, form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1H-


indene, dihydro-benzo[1,4]dioxine or benzo[1,3]dioxole moiety.

5 14. The use according to claim 13 wherein R₃ is propoxy and R₄ and R₅ together with the phenyl ring to which they are attached, form a naphthalene-1-yl or 5,6,7,8-tetrahydronaphthalen-1-yl moiety.

10 15. The use according to claim 1 or 2 of 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
1-phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-
15 pyrazolidine-3,5-dione;
4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-methoxybenzylidene)-1-phenyl-pyrazolidine-3,5-dione;
20 4-(2,4-dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(4-ethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(3-methyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-
25 3,5-dione;
4-(4-butoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(4-hexyloxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
30 4-(3-methyl-4-pentyloxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(4-cyclopropylmethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;
4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione;
35 4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzonitrile;

- 1- (2-chloro-phenyl) -4- (2,3-dimethyl-4-propoxy-benzylidene) -
pyrazolidine-3,5-dione;
4- (2,3-dimethyl-4-propoxy-benzylidene) -pyrazolidine-3,5-
dione;
5 4- (2,3-dimethyl-4-pent-1-ynyl-benzylidene) -1-phenyl-
pyrazolidine-3,5-dione;
4- (2,3-dimethyl-4-pentyl-benzylidene) -1-phenyl-
pyrazolidine-3,5-dione;
1-phenyl-4- (4-propoxy-naphthalen-1-ylmerthylene) -
10 pyrazolidine-3,5-dione;
4- (2,3-dimethyl-4-pentyl-benzylidene) -pyrazolidine-3,5-
dione;
4- (4-propoxy-naphthalen-1-ylmethylene) -pyrazolidine-3,5-
dione;
15 1-phenyl-4- (4-propoxy-benzylidene) -pyrazolidine-3,5-dione;
4- (4-butoxy-benzylidene) -1-phenyl-pyrazolidine-3,5-dione;
4- (4-cyclobutylmethoxy-3-methyl-benzylidene) -1-phenyl-
pyrazolidine-3,5-dione;
4- [3-methyl-4- (3-methyl-butoxy) -benzylidene] -1-phenyl-
20 pyrazolidine-3,5-dione;
4- (4-isobutoxy-3-methyl-benzylidene) -1-phenyl-pyrazolidine-
3,5-dione;
4- (4-cyclopentyloxy-2,3-dimethyl-benzylidene) -1-phenyl-
pyrazolidine-3,5-dione;
25 4- (3-methyl-4-propoxy-benzylidene) -1-pyridin-2-yl-
pyrazolidine-3,5-dione;
4- (2,3-dimethyl-4-propoxy-benzylidene) -1- (4-methyl-phenyl) -
pyrazolidine-3,5-dione;
4- (4-cyclopentyloxy-2,3-dimethyl-benzylidene) -pyrazolidine-
30 3,5-dione;
4- (2,3-dimethyl-4-propoxy-benzylidene) -1-pyridin-4-yl-
pyrazolidine-3,5-dione; and
4- (2,3-dimethyl-4-pent-1-ynyl-benzylidene) -pyrazolidine-
3,5-dione.
- 35

16. Compounds of the general formula



(III)

including their geometric isomers and tautomers and mixtures thereof as well as their salts, esters and
5 prodrugs mentioned in claim 1, wherein

R₁ is as defined in any one of claims 1 and 3 to 5;
R₃ is alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkoxy, alkoxyalkoxy, alkenyloxy, cycloalkoxy or cycloalkylalkoxy;
and

10 R₄ and R₅, each independently of the other, are halogen, hydroxy, alkyl or alkoxy, or, together with the phenyl ring to which they are attached, form a fused, optionally substituted carbocyclic or heterocyclic ring system, with the proviso that

15 (i) if R₁ is 4-iodophenyl and R₃ is hydroxy, R₄ and R₅ together with the phenyl ring to which they are attached may not be naphthalen-1-yl and

(ii) if R₁ is phenyl and R₃ is methoxy, R₄ and R₅ may not both be methoxy.

20 17. Compounds according to claim 16 wherein R₃ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkoxy, cycloalkylalkoxy, hydroxyalkoxy or alkoxyalkoxy, R₄ is halogen, alkyl or alkoxy and R₅ is alkyl or alkoxy.

25 18. Compounds according to claim 17 wherein R₃ is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, but-1-enyl, pent-1-enyl, but-1-ynyl, pent-1-ynyl, methoxy, ethoxy, propoxy, butoxy, isobutoxy, 3-methyl-butoxy, pentyloxy, cyclopentyloxy, hexyloxy, 30 cyclopropylmethoxy, cyclobutylmethoxy, 2-hydroxy-ethoxy, 2-

methoxy-ethoxy, R_4 is chloro, bromo, methyl or methoxy, and R_5 is methyl or methoxy.

19. Compounds according to claim 16 wherein R_3 is
5 alkoxy and R_4 and R_5 together with the phenyl ring to which they are attached, form an optionally substituted naphthalene, tetrahydronaphthalene, indane, 1H-indene, dihydro-benzo[1,4]dioxine or benzo[1,3]dioxole ring system.

10 20. Compounds according to claim 19 wherein R_3 is propoxy and R_4 and R_5 together with the phenyl ring to which they are attached, form a naphthalene-1-yl or 5,6,7,8-tetrahydronaphthalen-1-yl moiety.

15 21. 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-phenyl-pyrazolidine-3,5-dione.

22. 1-Phenyl-4-(4-propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione.

20

23. 4-(2,3-Dimethyl-4-propoxy-benzylidene)-1-(4-fluoro-phenyl)-pyrazolidine-3,5-dione.

24. 4-(4-Propoxy-5,6,7,8-tetrahydro-naphthalen-1-ylmethylene)-pyrazolidine-3,5-dione.

25

25. 4-(2,3-Dimethyl-4-methoxybenzylidene)-1-phenyl-pyrazolidine-3,5-dione;

4-(2,4-dimethoxy-3-methyl-benzylidene)-1-phenyl-pyrazolidine-3,5-dione;

30

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-2-yl-pyrazolidine-3,5-dione;

4-[4-(2,3-dimethyl-4-propoxy-benzylidene)-3,5-dioxo-pyrazolidin-1-yl]-benzonitrile;

35

1-(2-chloro-phenyl)-4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-1-phenyl-
pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pentyl-benzylidene)-1-phenyl-
pyrazolidine-3,5-dione;

5 1-phenyl-4-(4-propoxy-naphthalen-1-ylmerthylene)-
pyrazolidine-3,5-dione;

4-(2,3-dimethyl-4-pentyl-benzylidene)-pyrazolidine-3,5-
dione; and

10 4-(4-propoxy-naphthalen-1-ylmethyle)ne)-pyrazolidine-3,5-
dione.

26. 4-(4-Cyclopentyloxy-2,3-dimethyl-benzylidene)-1-
phenyl-pyrazolidine-3,5-dione;

15 4-(2,3-dimethyl-4-propoxy-benzylidene)-1-(4-methyl-phenyl)-
pyrazolidine-3,5-dione;

4-(4-cyclopentyloxy-2,3-dimethyl-benzylidene)-pyrazolidine-
3,5-dione;

4-(2,3-dimethyl-4-propoxy-benzylidene)-1-pyridin-4-yl-
pyrazolidine-3,5-dione; and

20 4-(2,3-dimethyl-4-pent-1-ynyl-benzylidene)-pyrazolidine-
3,5-dione.

27. Compounds according to any one of claims 16 to 26
for use as pharmaceutically active ingredients.

25


28. A pharmaceutical composition containing a compound
according to any one of claims 16 to 26 and a
pharmaceutically inert carrier.

30

29. The use according to claim 1 or 2 of compounds
according to any one of claims 16 to 19.

35

30. A Process for the manufacture of compounds
according to any one of claims 16 to 26 which comprises
condensing a pyrazolidinedione of the general formula (IV),
as shown in the following reaction scheme, wherein R₁, R₃,
R₄ and R₅ are as defined in claim 16,



with an aldehyde of the above general formula (V).

31. A pyrazolidinedione of the general formula (IV) as indicated in claim 30, selected from:


- 1-pyridin-2-yl-pyrazolidine-3,5-dione;
- 1-(4-methoxy-phenyl)-pyrazolidine-3,5-dione;
- 4-(3,5-dioxo-pyrazolidin-1-yl)-benzonitrile;
- 1-(2-methyl-phenyl)-pyrazolidine-3,5-dione; and
- 1-pyridin-4-yl-pyrazolidine-3,5-dione.

32. An aldehyde of the general formula (V) as indicated in claim 30 selected from:

- 4-cyclopentyloxy-2,3-dimethyl-benzaldehyde;
- 4-propoxy-5,6,7,8-tetrahydro-naphthalene-1-carbaldehyde;
- 2,3-dimethyl-4-pent-1-ynyl-benzaldehyde; and
- 2,3-dimethyl-4-pentyl-benzaldehyde.

Abstract

Pyrazolidinedione derivatives of the general formula



(I)

wherein R₁ is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; and R₂ is aryl or heteroaryl; tautomers thereof; geometric isomers thereof and tautomers of these geometric isomers, including mixtures of individual compounds of formula (I), or tautomers thereof, and their geometric isomers, or tautomers thereof; pharmaceutically acceptable acid addition salts of compounds which are basic; pharmaceutically acceptable salts of compounds containing acidic groups with bases; pharmaceutically acceptable esters of compounds containing hydroxy or carboxy groups; prodrugs of compounds in which a prodrug forming group is present; as well as hydrates or solvates thereof; are active as platelet adenosine diphosphate receptor antagonists and can be used for the prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, particularly thrombosis, and, respectively, for the manufacture of corresponding medicaments.

Some, albeit not all, of the compounds of the above formula (I) are novel.